{"gene":"NFATC2","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1993,"finding":"NFATp (NFATC2) is a DNA-binding phosphoprotein that is a direct substrate for the phosphatase calcineurin in vitro, and forms a ternary complex with Fos and Jun proteins on composite DNA elements; the DNA-binding domains of Fos and Jun are required for NFATp-Fos-Jun-DNA complex formation.","method":"In vitro calcineurin phosphatase assay with purified NFATp; recombinant protein DNA-binding assays with Fos/Jun; mutagenesis of Fos/Jun DNA-binding domains","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of calcineurin-substrate relationship, direct protein-DNA and protein-protein interaction assays, replicated across multiple studies","pmids":["8397339"],"is_preprint":false},{"year":1993,"finding":"NFATp is the DNA-binding subunit of the NFAT transcription complex; a recombinant truncated form binds specifically to the NFAT site of the murine IL-2 promoter and forms a transcriptionally active complex.","method":"Protein purification from murine T cells; cDNA cloning; recombinant protein DNA-binding assay; reporter transcription assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical reconstitution of DNA binding and transcriptional activity, multiple orthogonal methods","pmids":["8235597"],"is_preprint":false},{"year":1995,"finding":"Phosphorylation of NFATp inhibits its DNA-binding activity and its ability to form an NFAT complex with Fos and Jun; dephosphorylation by calcineurin or alkaline phosphatase in vitro restores DNA binding and complex formation with Fos/Jun.","method":"Immunoblot, 32P metabolic labeling, in vitro calcineurin/alkaline phosphatase treatment, EMSA","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical demonstration of phosphorylation-dependent DNA binding, multiple orthogonal methods","pmids":["7657645"],"is_preprint":false},{"year":1995,"finding":"NFATp undergoes calcineurin-dependent dephosphorylation and nuclear translocation upon ionomycin stimulation in T cells; immunoprecipitated NFATp from unstimulated cells is dephosphorylated by calcineurin in vitro, confirming it is an in vitro calcineurin substrate.","method":"Subcellular fractionation, Western blot, immunoprecipitation, 32P labeling, in vitro calcineurin dephosphorylation assay, FK506 inhibition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct in vitro substrate assay combined with cellular fractionation, replicated finding across multiple labs","pmids":["7545680"],"is_preprint":false},{"year":1996,"finding":"NFAT1 (NFATp/NFATC2) directly interacts with calcineurin through an N-terminal region conserved among NFAT family members; both phosphorylated and dephosphorylated forms of NFATp bind calcineurin, and this binding is blocked by the FK506-FKBP12 complex.","method":"Pulldown of NFATp from T cell lysates on immobilized calcineurin; inhibition with FK506-FKBP12 complex","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct physical interaction demonstrated, replicated by independent lab (PMID 8631904), FK506-FKBP12 competition control","pmids":["8576111","8631904"],"is_preprint":false},{"year":1996,"finding":"Calcineurin activity levels directly control the activation state of NFAT1: cessation of calcium signaling (EGTA, ionomycin removal) or addition of cyclosporin A causes rapid rephosphorylation of NFAT1 and its re-export to the cytoplasm, reversing nuclear accumulation and DNA binding.","method":"Subcellular fractionation, Western blot, cyclosporin A/EGTA/ionomycin pharmacological manipulation in T cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple pharmacological interventions, reciprocal reversibility demonstrated, consistent with calcineurin-substrate relationship","pmids":["8631904"],"is_preprint":false},{"year":1994,"finding":"NFATp binds to two sites within the κ3 element of the TNF-α promoter, and occupancy of both sites is required for calcium-stimulated, cyclosporin A-sensitive TNF-α gene induction in T cells.","method":"EMSA, promoter-reporter assays, cyclosporin A inhibition, site mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct DNA-binding and promoter functional assays with site-specific mutagenesis","pmids":["7982959"],"is_preprint":false},{"year":1996,"finding":"NFATp cooperates with ATF-2/Jun bound to an adjacent CRE site for TNF-α gene transcription in T cells; ATF-2 and Jun bind noncooperatively with NFATp in vitro, but the composite CRE/κ3 site shows dramatically higher transcriptional activity than κ3 alone, indicating in vivo cooperation.","method":"EMSA, promoter-reporter assays, T cell stimulation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct DNA-binding and transcriptional assays, functional in vivo cooperation demonstrated","pmids":["8552071"],"is_preprint":false},{"year":1995,"finding":"On the GM-CSF enhancer composite elements, NFATp and AP-1 bind cooperatively, and this cooperativity requires a specific spacing (9 bp) between GGA and TCA motifs; a site with 15 bp spacing supports strong independent but no cooperative binding of AP-1 and NFATp and functions poorly as an enhancer.","method":"EMSA, methylation interference, DNase footprinting, reporter assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical and functional dissection with quantitative spacing analysis, multiple methods","pmids":["7891702"],"is_preprint":false},{"year":1995,"finding":"In the cooperative NFAT-AP-1 complex on the IL-2 ARRE2 element, AP-1 (Fos-Jun) adopts a single orientation (Jun proximal, Fos distal to NFATp) through protein-protein contacts; in solution AP-1 binds as a mixture of orientational isomers, but NFATp locks a single orientation.","method":"Affinity cleaving experiments, protein cross-linking, EMSA","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with affinity-cleaving and cross-linking to define orientation, single lab","pmids":["7583146"],"is_preprint":false},{"year":1995,"finding":"The vitamin D receptor (VDR) directly competes with NFATp/AP-1 complex formation at the NF-AT-1 element of the IL-2 promoter; VDR-RXR heterodimer blocks NFATp/AP-1 complex formation and stably associates with the NF-AT-1 element; VDR DNA-binding is necessary but not sufficient for repression.","method":"In vitro competition assays with partially purified proteins, order-of-addition and off-rate experiments, cotransfection reporter assays, VDR DNA-binding domain mutants","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted competition in vitro with purified proteins, in vivo mutagenesis validation, single lab","pmids":["7565732"],"is_preprint":false},{"year":1999,"finding":"VDR competes with NFAT1 for binding to the GM-CSF NFAT-AP-1 composite site; overexpression of NFAT1 relieves VDR-dependent repression; VDR also directly interacts with c-Jun (demonstrated by GST coprecipitation) and stabilizes Jun-Fos binding adjacent to the NFAT1 binding site, providing a two-hit inhibitory mechanism.","method":"Transient transfection reporter assays, EMSA competition, GST coprecipitation, FLAG-VDR immunoprecipitation from nuclear extracts","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reconstituted competition, direct protein-protein interaction by GST pulldown, in vivo rescue experiments","pmids":["10330159"],"is_preprint":false},{"year":1996,"finding":"TCR stimulation leads to rapid (<minutes) calcineurin-dependent dephosphorylation, nuclear translocation, and increased DNA binding of NFAT1, followed hours later by phorbol ester-facilitated rephosphorylation and cytoplasmic re-export; late deactivation is facilitated by PKC-dependent pathways and inhibitors of capacitative calcium entry.","method":"Subcellular fractionation, EMSA, Western blot, pharmacological inhibition (cyclosporin A, PMA, ionomycin, EGTA)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods, temporal dissection of activation/deactivation cycle","pmids":["8668212"],"is_preprint":false},{"year":2000,"finding":"p38 MAPK phosphorylates NFATp in vitro and interacts with NFATp in vivo; activation of p38 (via MKK6) counteracts calcium-induced nuclear accumulation of NFATp (but not NFATc) and inhibits NFATp-driven transcription; p38-mediated nuclear export of NFATp is CRM1-dependent (Leptomycin B-sensitive).","method":"In vitro kinase assay, co-immunoprecipitation, cotransfection with activated MKK6/p38, nuclear/cytoplasmic fractionation, Leptomycin B treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro phosphorylation assay combined with cell-based fractionation and pharmacological inhibition, multiple orthogonal methods","pmids":["10788511"],"is_preprint":false},{"year":2003,"finding":"Crystal structure of NFAT1 (NFATC2) bound as a dimer to the HIV-1 LTR κB element reveals a novel asymmetric dimerization mode through the C-terminal Rel homology subdomain, distinct from other Rel family dimers; both N- and C-terminal subdomains form protein-protein contacts encircling the DNA.","method":"X-ray crystallography","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure, high-resolution direct structural determination","pmids":["12949493"],"is_preprint":false},{"year":1998,"finding":"NFAT1 induces cooperative DNA bending at the ARRE2 site in the NFAT1-Fos-Jun ternary complex that differs from the sum of individual bends; NFAT1 interaction with the Fos-Jun leucine zipper (specifically three N-terminal residues) can reverse the orientation of Fos-Jun heterodimer binding on DNA.","method":"Gel electrophoretic phasing analysis, fluorescence resonance energy transfer (FRET) orientation assay, mutagenesis of Fos/Jun leucine zippers","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple biophysical and structural methods in one study, site-directed mutagenesis validation","pmids":["9653115"],"is_preprint":false},{"year":2008,"finding":"NFATp dimerization on the TNF promoter NFAT-bZIP element creates a dimer-specific function: the NFATp dimer and its bZIP partner bind noncooperatively to this element, whereas a monomer recruits bZIP cooperatively; NFATp dimer-specific activation subdomains interact with the coactivator CBP and are required for transcriptional activation from the TNF element.","method":"Consensus binding site determination, DNase footprinting, transcriptional reporter assays, coactivator interaction assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple biochemical and functional methods, structure-function mapping, CBP interaction demonstrated","pmids":["19060202"],"is_preprint":false},{"year":2001,"finding":"NFATC2 is required intrinsically for skeletal muscle cell growth: NFATC2-null primary myotubes show reduced size and myonuclear number; retroviral re-expression of NFATC2 rescues these defects; NFATC2 controls a second phase of myoblast fusion (nuclear accretion) after initial myotube formation.","method":"NFATC2 knockout mouse analysis, primary muscle cell culture, retroviral rescue, morphometric measurement of myotube size and nuclear number","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined cellular phenotype, retroviral rescue, multiple readouts","pmids":["11309414"],"is_preprint":false},{"year":2003,"finding":"Prostaglandin F2α (PGF2α) stimulates skeletal muscle cell growth through the FP receptor and requires NFATC2 activation: PGF2α activates NFAT, and NFATC2-null myotubes fail to grow or accrue nuclei in response to PGF2α, identifying the first intersection between prostaglandin receptor signaling and NFAT.","method":"PGF2α/analogue treatment of primary muscle cultures, NFAT reporter assay, NFATC2 knockout myotubes, nuclear accretion counts","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined pathway and phenotypic readout, pharmacological receptor activation","pmids":["12695501"],"is_preprint":false},{"year":2000,"finding":"NFATp (NFATC2) functions as a repressor of chondrogenesis in vivo: mice lacking NFATp spontaneously develop cartilage from extraarticular connective tissue, and NFATp overexpression in cartilage cell lines extinguishes the cartilage phenotype; NFATp expression is regulated during mesenchymal stem cell chondrogenic differentiation.","method":"NFATp knockout mouse histology, overexpression in chondrocyte cell lines, cartilage marker expression analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with spontaneous phenotype, confirmed by overexpression in cell lines, multiple readouts","pmids":["10620601"],"is_preprint":false},{"year":2002,"finding":"NFATc2 negatively regulates CDK4 expression by binding a canonical NFAT site in the CDK4 promoter in a calcium-sensitive, FK506/CsA-sensitive, and histone deacetylase-sensitive manner; ectopic NFATc2 inhibits CDK4 promoter activity; calcineurin Aα−/− and NFATc2−/− mice have elevated CDK4 protein levels.","method":"Promoter-reporter assays, pharmacological inhibition (FK506, CsA, HDAC inhibitors), NFATc2 overexpression, Western blot of CDK4 in KO mice","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — promoter binding demonstrated, confirmed in two independent KO mouse models, multiple pharmacological validations","pmids":["12453415"],"is_preprint":false},{"year":2002,"finding":"IL-6 upregulates NFATc2 protein levels in CD4+ T cells, increasing NFAT transcriptional activity, which drives IL-4 production; CD4+ T cells lacking NFATc2 fail to produce IL-4 in response to IL-6, preventing Th2 differentiation.","method":"NFATc2 knockout CD4+ T cells, IL-6 stimulation, IL-4 ELISA, NFAT transcriptional reporter, cyclosporin A inhibition","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined molecular and cellular phenotype, NFAT reporter confirmation","pmids":["12093869"],"is_preprint":false},{"year":2002,"finding":"NFAT1 (NFATc2) and NFAT2 are both positive regulators of IL-4 gene transcription when constitutively active (Ala substitution) forms are expressed; the disparate knockout phenotypes reflect differential regulation of the two proteins rather than intrinsic differences in DNA binding or transcriptional activity at the IL-4 locus.","method":"Constitutively active (phospho-Ser→Ala) mutant NFAT overexpression, IL-4 reporter and secretion assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with defined mutants, single lab, two methods","pmids":["12355451"],"is_preprint":false},{"year":2005,"finding":"NFATc2 directly binds the IL-21 proximal promoter and activates its transcription in Th2 cells; T-bet represses IL-21 transcription in Th1 cells by inhibiting NFATc2 binding to the IL-21 promoter.","method":"Promoter-reporter assays, chromatin immunoprecipitation (ChIP), EMSA, T-bet overexpression/NFATc2 competition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct ChIP, EMSA, and functional reporter assays, T-bet competition mechanism defined","pmids":["15684054"],"is_preprint":false},{"year":2009,"finding":"GSK-3β mediates inhibition of NFAT (including NFAT1) activity downstream of Akt1; GSK-3β-dependent NFAT inhibition leads to proteasomal degradation of NFAT and blocks breast cancer cell migration; GSK-3β mutants unresponsive to Akt reveal that Akt-mediated inhibition of migration is mediated through GSK-3β.","method":"GSK-3β shRNA and selective inhibitor, GSK-3β mutants unresponsive to Akt, NFAT reporter, proteasome inhibitor assays, migration assay","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological approaches, proteasomal degradation pathway defined, single lab","pmids":["19258413"],"is_preprint":false},{"year":2011,"finding":"NFATc2 in pancreatic cancer cells targets the p15(INK4b) promoter and induces heterochromatin formation through sequential recruitment of histone methyltransferase Suv39H1, H3K9 trimethylation, and HP1γ docking; inactivation of NFATc2 disrupts this repressor complex, restoring p15(INK4b) expression and inhibiting cancer growth.","method":"ChIP, co-immunoprecipitation, DNA pulldown, reporter assays, xenograft tumor models, H3K9me3 ChIP","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ChIP, co-IP, functional reporter), confirmed in vivo in xenograft model","pmids":["22079596"],"is_preprint":false},{"year":2012,"finding":"NFAT1 (NFATC2) directly binds the mdm2 P2 promoter in vitro and in vivo and upregulates MDM2 transcription; enforced NFAT1 expression elevates MDM2 protein and reduces p53 function after DNA damage.","method":"EMSA, ChIP, reporter assays, NFAT1 overexpression, Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct EMSA and ChIP for promoter binding, functional gain-of-function, multiple methods","pmids":["22787160"],"is_preprint":false},{"year":2012,"finding":"VRK2 directly interacts with and phosphorylates NFAT1 at Ser-32 within its N-terminal transactivation domain; this phosphorylation by VRK2 increases NFAT1-dependent transcription and COX-2 expression through the NFAT1 binding site in the COX-2 promoter, promoting tumor cell invasion.","method":"In vitro kinase assay, co-immunoprecipitation, luciferase reporter with COX-2 promoter, VRK2 RNAi, invasion assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay identifying phosphorylation site (Ser-32), functional reporter and cellular invasion assay","pmids":["23105117"],"is_preprint":false},{"year":2016,"finding":"LRRK2 kinase selectively phosphorylates NFATc2 and induces its nuclear translocation in microglia; α-synuclein activates LRRK2, which phosphorylates NFATc2 to drive neuroinflammatory TNF-α and IL-6 expression; genetic or pharmacological LRRK2 inhibition reduces NFATc2 nuclear translocation and microglial neurotoxicity.","method":"Primary mouse microglia cultures, LRRK2 genetic knockout/pharmacological inhibition, nuclear fractionation, cytokine ELISA, in vivo synucleinopathy mouse model","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway with genetic and pharmacological validation, confirmed in vivo, published in Science Translational Medicine","pmids":["33055242"],"is_preprint":false},{"year":2016,"finding":"GSK-3β phosphorylates NFATc2 at SP2 motif to stabilize NFATc2 protein in the nucleus of pancreatic cancer cells; additionally, GSK-3β maintains NFATc2 activation through stabilization of NFATc2-STAT3 complexes via GSK-3β-mediated STAT3 phosphorylation at Y705, stimulating euchromatin formation at NFATc2 target promoters such as CDK6.","method":"Co-immunoprecipitation, ChIP, reporter assay, GSK-3β inhibition/activation, xenograft and GEMM models","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP and ChIP for complex formation, functional readouts in multiple in vivo models, mechanistic detail at phosphorylation site level","pmids":["26823495"],"is_preprint":false},{"year":2016,"finding":"NFAT1 (NFATC2) directly regulates IL8 and MMP3 transcription in melanoma cells to promote tumor growth and lung metastasis; silencing NFAT1 reduces IL8 and MMP3 expression, and restoration rescues expression to baseline; both genes are validated as direct transcriptional targets by rescue experiments.","method":"NFAT1 stable silencing, microarray, qRT-PCR, overexpression rescue, in vivo xenograft/metastasis assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with rescue, in vivo validation, but no direct ChIP shown in abstract","pmids":["27013197"],"is_preprint":false},{"year":2010,"finding":"NFATc2 directly binds two NFAT-binding sites in the 5'-flanking region of the mouse Ccr9 gene and cooperates with the RAR/RXR complex bound to an adjacent RA response element half-site to drive CCR9 expression; NFATc2 enhances RARα binding to the RA response element; NFATc1, though it also binds the same sites and RARα/RXRα, inhibits NFATc2-dependent promoter activity.","method":"Reporter assays, DNA-affinity precipitation, direct protein interaction assay, murine naive CD4+ T cells, cyclosporin A inhibition","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct DNA binding, protein-protein interaction, and functional reporter assays, detailed mechanistic dissection","pmids":["21148038"],"is_preprint":false},{"year":2021,"finding":"NFATC2 induces β cell proliferation and activates ~2200 transcriptional targets in human islets; NFATC2 response elements in the SOX2 3' enhancer and ALDH1A1 5' enhancer are identified; NFATC2 induces Nr4a1, which is required for much of the proliferative effect; FOXP family transcription factors cooperate with NFATC2 to regulate β cell proliferation.","method":"Active NFATC2 expression in human islets, RNA-seq, ChIP-seq, FOXP1/2/4 triple KO islets, Nr4a1 deletion, ATAC-seq","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — integrated genomics (ChIP-seq + RNA-seq + ATAC-seq), genetic validation with KO models, multiple orthogonal methods","pmids":["34491912"],"is_preprint":false},{"year":2014,"finding":"NFATc2 mediates epigenetic modification of DC cytokine and chemokine gene loci in response to dectin-1 stimulation; genome-wide NFATc2 binding (ChIP-seq) reveals occupancy at cytokine/chemokine loci, and NFATc2 binding is required to induce the H3K4me3 activating histone mark at these loci.","method":"ChIP-seq for NFATc2 genome-wide binding, H3K4me3 ChIP, gene expression profiling, dectin-1 stimulation of DCs","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq, epigenetic mark validated by ChIP, comprehensive gene expression integration","pmids":["25550437"],"is_preprint":false},{"year":2022,"finding":"Dapl1 restrains NFATc2 activation in CD8+ T cells; Dapl1 deficiency enhances NFATc2 activation, improving effector function and preventing exhaustion; exhausted CD8+ T cells display attenuated NFATc2 activation due to Tim3-mediated feedback inhibition, which Dapl1 deletion rescues.","method":"Dapl1 KO mice, T cell adoptive transfer, NFATc2 reporter/activation assay, Tim3 feedback inhibition analysis, tumor models","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with mechanistic pathway defined, multiple in vivo models, published in Nature Cell Biology","pmids":["35773432"],"is_preprint":false},{"year":2017,"finding":"NFATc2 binds the 3' enhancer region of SOX2, coupling NFATc2/SOX2 to upregulate ALDH1A1 via its 5' enhancer; this NFATc2/SOX2/ALDH1A1 axis attenuates oxidative stress from cancer drug treatment, promoting drug resistance in lung cancer tumor-initiating cells.","method":"NFATc2 KD/OE, reporter assays, ChIP for NFATc2 binding to SOX2 and ALDH1A1 enhancers, sphere formation and in vivo tumorigenesis assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter validation of binding, functional rescue, single lab","pmids":["28737489"],"is_preprint":false},{"year":2020,"finding":"NFAT1 directly binds the MMP-9 promoter in melanoma cells and drives MMP-9 expression; CD147 activates NFAT1 via the intracellular Ca2+-calcineurin pathway; knockdown of NFAT1 suppresses melanoma metastasis in an NFAT1-dependent manner; CD147 knockdown reduces NFAT1-MMP-9 promoter binding.","method":"Luciferase reporter with MMP-9 promoter, ChIP for NFAT1 at MMP-9 promoter, siRNA knockdown, Ca2+ signaling assays","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP and reporter assays for target binding, functional knockdown, single lab","pmids":["32339381"],"is_preprint":false},{"year":2021,"finding":"FGF19/FGFR4 signaling activates store-operated Ca2+ entry (SOCE) via PLCγ and ERK1/2 pathways, which activates calcineurin and promotes NFATc2 nuclear translocation; nuclear NFATc2 transcriptionally activates stemness genes (NANOG, OCT4, SOX2) and FGF19 itself, creating a positive feedback loop sustaining liver cancer stem cell self-renewal.","method":"Ca2+ imaging, calcineurin activity assay, NFATc2 nuclear fractionation, ChIP for NFATc2 at stemness gene promoters, sphere assays, FGFR4 knockdown/overexpression","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct binding, Ca2+ and calcineurin activity assays, functional rescue, single lab","pmids":["33754043"],"is_preprint":false},{"year":2016,"finding":"NFAT1 (NFATc2) directly binds to and activates the IL8 gene promoter in breast cancer cells, leading to IL8 secretion that promotes primary human neutrophil migration; NFAT1-mediated IL8 production is stimulated by thapsigargin and suppresses nascent tumor growth by a non-cell-autonomous mechanism.","method":"ChIP for NFAT1 at IL8 promoter, NFAT reporter, thapsigargin stimulation, neutrophil migration assay, xenograft tumor growth","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP showing promoter binding, functional in vitro and in vivo validation, single lab","pmids":["25735562"],"is_preprint":false},{"year":2015,"finding":"NFATc2 controls melanoma dedifferentiation by inducing expression of membrane-bound TNF-α (mTNF-α), which then regulates a c-Myc–Brn2 axis to suppress MITF and maintain a dedifferentiated state; NFATc2 silencing upregulates MITF, melanocyte differentiation antigens, and pigmentation.","method":"siRNA and shRNA silencing, NFATc2 inhibitor, TNF-α neutralization, c-Myc inhibition, Brn2 silencing, FACS, cytolytic T cell assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sequential pathway dissection by multiple knockdowns, but no direct ChIP for mTNF-α promoter shown in abstract","pmids":["26387540"],"is_preprint":false},{"year":2022,"finding":"NFAT1 is upregulated in spinal microglia after nerve ligation via TET2-mediated DNA demethylation; NFAT1 directly binds promoters of Itgam, Tnf, Il-1b, and c-Myc in the spinal cord; NFAT1 promotes microglial proliferation through c-MYC; microglia-specific deletion of Nfat1 attenuates neuropathic pain.","method":"Microglia-specific Nfat1 KO mice, ChIP for NFAT1 binding, c-MYC overexpression, intrathecal siRNA injection, TET2/DNA methylation analysis","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP at multiple promoters, genetic KO with defined phenotype, single lab","pmids":["35892263"],"is_preprint":false},{"year":2012,"finding":"NFAT1 physically interacts with Stat5 through Stat5's DNA-binding and transactivation domains; ectopic NFAT1 inhibits Stat5 transactivation, Stat5-mediated transcription, and Stat5a binding to its target promoter; conversely, Stat5 inhibits NFAT1 signaling, establishing mutual negative cross-talk.","method":"Co-immunoprecipitation, luciferase reporter, ChIP for Stat5a, NFAT1 overexpression and RNAi, VIVIT (NFAT inhibitor) treatment","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and functional reporter assays, single lab","pmids":["21964595"],"is_preprint":false},{"year":2006,"finding":"NFAT1 is required for B cell clonal anergy: NFAT1-deficient mice crossed with anti-lysozyme Ig transgenic/soluble lysozyme double transgenic mice show relief of B cell anergy, demonstrating that NFAT1 mediates peripheral B cell tolerance to self-antigen.","method":"NFAT1 KO mice crossed with double-transgenic anergy model, serum antibody levels, B cell numbers, proliferation assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in defined anergy model, clean KO with specific phenotypic readout, single lab","pmids":["16849457"],"is_preprint":false},{"year":2012,"finding":"NFAT1 mediates the induction of anergy-associated genes in CD4+ T cells in response to cancer antigen stimulation without costimulation; NFAT1-deficient antigen-specific CD4+ T cells show blunted anergy induction and enhanced anti-tumor responses in a murine melanoma model.","method":"NFAT1 KO mouse melanoma model, antigen-specific CD4+ T cell cytokine assays, NFAT1-deficient T cell transfer","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO in defined tumor-anergy model, specific mechanistic pathway placement, single lab","pmids":["22865456"],"is_preprint":false},{"year":2016,"finding":"NFATc2 and NFKB1/RELA directly bind a core regulatory element (CRE, -540/-80 bp from TSS) in the Ets1 promoter to trans-activate Ets1 transcription in metastatic breast cancer cells; CRISPR/Cas9 deletion of the CRE reduces Ets1 expression and tumor invasiveness-related gene programs.","method":"ChIP for NFATc2 and NFKB1/RELA at Ets1 CRE, EMSA, CRISPR/Cas9 CRE deletion, reporter assays","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP and CRISPR genetic validation, functional transcriptional readout, single lab","pmids":["30467308"],"is_preprint":false},{"year":2004,"finding":"IL-15 specifically recruits NFAT1 (but not NFAT2) to the κB-like NFAT site in the CX3CR1 promoter to repress CX3CR1 expression, while IL-2 recruits NFAT2 to activate CX3CR1; NFAT1-deficient mice fail to show IL-15-dependent CX3CR1 downregulation.","method":"ChIP for NFAT1/NFAT2 at CX3CR1 promoter, NFAT1 KO mice, NFAT inhibitors (CsA, VIVIT), mutation of κB-NFAT site, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP, genetic KO, pharmacological and mutation-based validation, consistent in vivo confirmation","pmids":["15347678"],"is_preprint":false}],"current_model":"NFATC2 (NFATp/NFAT1) is a calcium/calcineurin-regulated transcription factor that resides in the cytoplasm in a hyperphosphorylated, DNA-binding-incompetent state; calcineurin dephosphorylates it directly, triggering nuclear translocation and activation of cytokine genes (IL-2, IL-4, IL-21, TNF-α, GM-CSF) through cooperative ternary complexes with Fos-Jun (AP-1) on composite NFAT-AP-1 elements; nuclear export is driven by rephosphorylation via kinases including p38 MAPK and GSK-3β (the latter also controlling proteasomal stability and STAT3 complex formation); the protein can also act as a transcriptional repressor (of CDK4, p15(INK4b), CX3CR1, Cyclin E, and chondrogenic genes) and structurally can function as both a monomer and asymmetric dimer on DNA, with dimer-specific activation subdomains recruiting the CBP coactivator; beyond immune cells, NFATC2 controls skeletal muscle growth (via IL-4 and prostaglandin F2α signaling), cartilage homeostasis, β-cell proliferation (through Nr4a1 and FOXP co-factors), and is aberrantly activated in multiple cancers where it drives targets including MDM2, MMP3, MMP-9, IL8, SOX2/ALDH1A1, and Ets1."},"narrative":{"mechanistic_narrative":"NFATC2 (NFATp/NFAT1) is a calcium/calcineurin-regulated transcription factor that converts T-cell receptor and other Ca2+-mobilizing signals into programs of cytokine gene expression and broader cell-fate decisions [PMID:8235597, PMID:7545680]. In resting cells it is a hyperphosphorylated, DNA-binding-incompetent phosphoprotein; calcineurin binds NFATC2 directly through a conserved N-terminal region and dephosphorylates it, restoring DNA binding and driving nuclear accumulation, while cessation of Ca2+ signaling, cyclosporin A, or FK506-FKBP12 reverses these steps and re-exports the protein [PMID:8397339, PMID:7657645, PMID:8576111, PMID:8631904]. The activation cycle is closed by kinases that rephosphorylate NFATC2 to promote CRM1-dependent nuclear export and turnover: p38 MAPK opposes its nuclear accumulation [PMID:10788511], and GSK-3β both targets NFAT for proteasomal degradation downstream of Akt [PMID:19258413] and, paradoxically in pancreatic cancer, stabilizes nuclear NFATC2 and its STAT3 complexes to maintain target-gene chromatin in an active state [PMID:26823495]. Once nuclear, NFATC2 acts as the DNA-binding subunit of composite enhancer complexes, cooperating with AP-1 (Fos-Jun) and ATF-2/Jun on spacing-constrained NFAT-AP-1 elements of IL-2, GM-CSF, and TNF-α promoters, where it locks AP-1 orientation and bends DNA through specific protein-protein contacts [PMID:8397339, PMID:8552071, PMID:7891702, PMID:7583146, PMID:9653115]. Structurally it binds DNA as a monomer or as a novel asymmetric Rel-homology dimer, and the dimer form carries activation subdomains that recruit the CBP coactivator [PMID:12949493, PMID:19060202]. Through these complexes NFATC2 drives cytokine and effector genes (TNF-α, IL-4, IL-21) and mediates T-cell anergy and B-cell tolerance [PMID:7982959, PMID:12093869, PMID:15684054, PMID:16849457, PMID:22865456], and it also functions as a sequence-specific repressor, silencing CDK4 and the p15(INK4b) locus via Suv39H1/H3K9me3/HP1γ heterochromatin assembly and repressing CX3CR1 [PMID:12453415, PMID:22079596, PMID:15347678]. Beyond immunity, NFATC2 is intrinsically required for skeletal myotube growth and nuclear accretion downstream of prostaglandin F2α/FP signaling [PMID:11309414, PMID:12695501], represses chondrogenesis [PMID:10620601], and drives β-cell proliferation through Nr4a1 and FOXP cofactors [PMID:34491912]. In cancer it is aberrantly activated to transcribe MDM2, MMP3, MMP-9, IL8, the SOX2/ALDH1A1 stemness-and-drug-resistance axis, and Ets1, promoting invasion, metastasis, and tumor-initiating-cell self-renewal [PMID:22787160, PMID:27013197, PMID:28737489, PMID:32339381, PMID:30467308].","teleology":[{"year":1993,"claim":"Established the foundational identity of NFATC2 as the DNA-binding subunit of the NFAT complex and as a direct calcineurin substrate that builds ternary complexes with AP-1.","evidence":"Protein purification, cDNA cloning, recombinant DNA-binding and reporter assays, and in vitro calcineurin phosphatase assays with Fos/Jun DNA-binding-domain mutagenesis","pmids":["8235597","8397339"],"confidence":"High","gaps":["Did not define the in vivo phosphorylation sites controlling activity","Cellular kinetics of translocation not yet resolved"]},{"year":1995,"claim":"Resolved the regulatory logic: phosphorylation directly blocks DNA binding and calcineurin-mediated dephosphorylation upon Ca2+ signaling triggers nuclear translocation, defining the on-switch.","evidence":"32P labeling, in vitro calcineurin/alkaline phosphatase treatment, EMSA, and subcellular fractionation with FK506 inhibition in T cells","pmids":["7657645","7545680"],"confidence":"High","gaps":["Calcineurin docking interface on NFATC2 not yet mapped","Off-switch kinases not identified"]},{"year":1996,"claim":"Mapped the physical calcineurin–NFATC2 interaction and showed calcineurin activity bidirectionally controls activation state, completing the reversible activation/deactivation cycle.","evidence":"Calcineurin pulldown with FK506-FKBP12 competition; pharmacological manipulation (EGTA, CsA, ionomycin, PMA) with fractionation and EMSA","pmids":["8576111","8631904","8668212"],"confidence":"High","gaps":["Identity of the rephosphorylating kinases for export not yet established","Capacitative Ca2+ entry link only pharmacologically inferred"]},{"year":1995,"claim":"Defined the biochemical basis of cooperative NFAT-AP-1 enhancer assembly, showing strict spacing requirements and NFATC2-imposed AP-1 orientation that distinguish functional from non-functional composite sites.","evidence":"EMSA, methylation interference, DNase footprinting, affinity-cleaving, cross-linking and reporter assays on GM-CSF and IL-2 elements","pmids":["7891702","7583146"],"confidence":"High","gaps":["Structural basis of the orientation lock not yet visualized","Coactivator recruitment not yet addressed"]},{"year":1994,"claim":"Extended NFATC2 target repertoire to the TNF-α promoter, showing dual-site occupancy and cooperation with adjacent ATF-2/Jun is required for calcium-driven, CsA-sensitive induction.","evidence":"EMSA, promoter-reporter assays, site mutagenesis, and CsA inhibition in T cells","pmids":["7982959","8552071"],"confidence":"High","gaps":["Whether monomer vs dimer binding distinguishes TNF-α regulation not yet resolved"]},{"year":1999,"claim":"Identified VDR as a competitive repressor that blocks NFATC2/AP-1 complex formation at IL-2 and GM-CSF elements, revealing transcription-factor competition as a mode of NFAT regulation.","evidence":"In vitro competition with purified proteins, EMSA, GST coprecipitation with c-Jun, FLAG-VDR IP, and reporter rescue by NFAT overexpression","pmids":["7565732","10330159"],"confidence":"High","gaps":["Physiological contexts where VDR competition dominates not defined"]},{"year":2003,"claim":"Provided the structural mechanism by solving the NFATC2 dimer on a κB element, revealing a novel asymmetric Rel-homology dimerization mode distinct from other Rel proteins.","evidence":"X-ray crystallography of NFAT1 bound to HIV-1 LTR κB DNA; FRET/phasing analysis of cooperative DNA bending in the ternary complex","pmids":["12949493","9653115"],"confidence":"High","gaps":["Functional consequence of dimerization not yet established at the time"]},{"year":2008,"claim":"Linked the dimer structure to function, showing NFATC2 dimer-specific activation subdomains recruit CBP and confer dimer-dependent transcriptional output at the TNF element.","evidence":"Consensus site determination, DNase footprinting, transcriptional reporters, and coactivator interaction assays","pmids":["19060202"],"confidence":"High","gaps":["In vivo prevalence of dimer vs monomer binding genome-wide unknown"]},{"year":2000,"claim":"Identified kinase off-switches: p38 MAPK phosphorylates and drives CRM1-dependent export of NFATC2, distinguishing its regulation from NFATc.","evidence":"In vitro kinase assay, co-IP, activated MKK6/p38 cotransfection, fractionation, and Leptomycin B inhibition","pmids":["10788511"],"confidence":"High","gaps":["Phospho-acceptor sites for p38 on NFATC2 not mapped"]},{"year":2001,"claim":"Demonstrated a non-immune, cell-intrinsic role: NFATC2 is required for a second phase of myoblast fusion and skeletal myotube growth.","evidence":"NFATC2-null primary myotubes, retroviral rescue, and morphometric measurement of size and myonuclear number","pmids":["11309414"],"confidence":"High","gaps":["Direct muscle-growth target genes not identified"]},{"year":2003,"claim":"Placed prostaglandin F2α/FP receptor signaling upstream of NFATC2 in muscle growth, the first prostaglandin-receptor–NFAT intersection.","evidence":"PGF2α treatment, NFAT reporter, and NFATC2-null myotube nuclear accretion assays","pmids":["12695501"],"confidence":"High","gaps":["Signaling steps linking FP receptor to calcineurin in muscle not detailed"]},{"year":2000,"claim":"Revealed NFATC2 as a repressor of differentiation: loss causes spontaneous cartilage formation, establishing it as a brake on chondrogenesis.","evidence":"NFATp knockout mouse histology and chondrocyte-line overexpression with cartilage-marker analysis","pmids":["10620601"],"confidence":"High","gaps":["Repressed chondrogenic target genes not molecularly defined"]},{"year":2004,"claim":"Showed cytokine-context selectivity in repression: IL-15 recruits NFATC2 specifically to repress CX3CR1, contrasting with IL-2/NFAT2 activation of the same gene.","evidence":"ChIP for NFAT1/NFAT2, NFAT1 KO mice, CsA/VIVIT inhibitors, and κB-NFAT site mutation reporter assays","pmids":["15347678"],"confidence":"High","gaps":["Mechanism converting NFATC2 from activator to repressor at this site unresolved"]},{"year":2002,"claim":"Defined direct gene-control roles in immune differentiation and cell cycle: NFATC2 drives IL-4 (downstream of IL-6) and IL-21, and represses CDK4 via HDAC-sensitive promoter binding.","evidence":"NFATc2 KO T cells, IL-4 ELISA, NFAT reporters, ChIP/EMSA at IL-21, CDK4 promoter-reporters and CDK4 levels in calcineurin/NFATc2 KO mice","pmids":["12093869","12355451","15684054","12453415"],"confidence":"High","gaps":["Switch between activator and repressor functions at different promoters not mechanistically unified"]},{"year":2006,"claim":"Established NFATC2 as an enforcer of tolerance/anergy in both B and T lymphocytes, framing it as a negative as well as positive immune regulator.","evidence":"NFAT1 KO crossed with anti-lysozyme anergy model; NFAT1-deficient antigen-specific CD4+ T cells in melanoma model","pmids":["16849457","22865456"],"confidence":"Medium","gaps":["Anergy-associated gene targets only partially defined","Single-lab models for each phenotype"]},{"year":2012,"claim":"Identified oncogenic activation routes: VRK2 phosphorylates NFAT1 at Ser-32 to boost COX-2-driven invasion, and NFAT1 transactivates MDM2 to suppress p53.","evidence":"In vitro kinase assay (Ser-32), co-IP, EMSA/ChIP at mdm2 P2 promoter, reporters, and invasion assays","pmids":["23105117","22787160"],"confidence":"High","gaps":["Whether VRK2 and the calcineurin axis converge on the same activation pool unknown"]},{"year":2016,"claim":"Resolved a context-specific GSK-3β role and chromatin mechanism in pancreatic cancer: GSK-3β stabilizes nuclear NFATc2 and NFATc2-STAT3 complexes, while NFATc2 builds Suv39H1/H3K9me3/HP1γ heterochromatin to silence p15(INK4b).","evidence":"Co-IP, ChIP (H3K9me3, target promoters), DNA pulldown, reporters, and xenograft/GEMM models","pmids":["26823495","22079596"],"confidence":"High","gaps":["Reconciliation with GSK-3β-driven NFAT degradation in other contexts not fully resolved"]},{"year":2009,"claim":"Placed NFAT downstream of Akt-GSK-3β signaling controlling proteasomal turnover and breast cancer migration, defining a degradation-based off-switch.","evidence":"GSK-3β shRNA/inhibitor, Akt-unresponsive GSK-3β mutants, NFAT reporter, proteasome inhibitors, and migration assays","pmids":["19258413"],"confidence":"Medium","gaps":["Degradation machinery and ubiquitin ligase not identified","Single lab"]},{"year":2017,"claim":"Defined NFATC2 cancer transcriptional programs driving invasion, metastasis, stemness, and drug resistance through direct targets including IL8, MMP3, MMP-9, Ets1, and the SOX2/ALDH1A1 axis.","evidence":"ChIP/reporters at target promoters and enhancers, knockdown/rescue, Ca2+/calcineurin assays, CRISPR CRE deletion, sphere and xenograft/metastasis assays","pmids":["28737489","27013197","32339381","30467308","25735562","33754043","26387540"],"confidence":"Medium","gaps":["Many targets validated in single tumor types and single labs","Direct ChIP missing for some targets"]},{"year":2021,"claim":"Mapped genome-wide NFATC2 programs in non-immune proliferation and epigenetic activation: ~2200 β-cell targets via Nr4a1 and FOXP cofactors, and dectin-1–induced H3K4me3 deposition at cytokine loci in dendritic cells.","evidence":"Active NFATC2 expression in human islets with RNA-seq/ChIP-seq/ATAC-seq, FOXP and Nr4a1 KO; ChIP-seq and H3K4me3 ChIP in dendritic cells","pmids":["34491912","25550437"],"confidence":"High","gaps":["Direct biochemical link between NFATC2 and the H3K4 methyltransferase not established"]},{"year":2022,"claim":"Extended NFATC2 regulation to T-cell exhaustion and microglial neuroinflammation: Dapl1/Tim3 restrains NFATc2 in CD8+ T cells, and LRRK2 phosphorylates NFATc2 to drive cytokine production via direct binding of inflammatory and proliferative promoters.","evidence":"Dapl1 KO mice with adoptive transfer/tumor models; LRRK2 KO/inhibition with nuclear fractionation and ELISA; microglia-specific Nfat1 KO with ChIP at Itgam/Tnf/Il1b/c-Myc","pmids":["35773432","33055242","35892263"],"confidence":"High","gaps":["LRRK2 phospho-site on NFATc2 not mapped","Interplay between calcineurin and these alternative kinase inputs unresolved"]},{"year":null,"claim":"How NFATC2 is switched between activator and repressor at a given locus, and how competing kinase inputs (calcineurin, p38, GSK-3β, VRK2, LRRK2) are integrated to set monomer vs dimer occupancy genome-wide, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking phosphorylation state to activator/repressor choice","Determinants of monomer vs dimer binding in vivo unknown","Cofactor code (CBP vs Suv39H1/HP1γ) selection not mechanistically defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,6,20,23,25,26,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,2,6,14,26,36]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[1,14]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,5,12,13,28,37]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,5,12]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[14,16,29]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,5,12,13,24]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,6,20,23,26,32]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,21,23,42,43,45]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[25,26,30,35,36,44]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[25,33]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[20,32]}],"complexes":["NFAT-AP-1 (Fos-Jun) ternary complex","NFATC2 asymmetric homodimer","NFATc2-Suv39H1-HP1γ repressor complex","NFATc2-STAT3 complex"],"partners":["PPP3 (CALCINEURIN)","FOS","JUN","ATF2","CREBBP (CBP)","STAT3","VDR","STAT5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13469","full_name":"Nuclear factor of activated T-cells, cytoplasmic 2","aliases":["NFAT pre-existing subunit","NF-ATp","T-cell transcription factor NFAT1"],"length_aa":925,"mass_kda":100.1,"function":"Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF or GM-CSF (PubMed:15790681). Promotes invasive migration through the activation of GPC6 expression and WNT5A signaling pathway (PubMed:21871017). Is involved in the negative regulation of chondrogenesis (PubMed:35789258). Recruited by AKAP5 to ORAI1 pore-forming subunit of CRAC channels in Ca(2+) signaling microdomains where store-operated Ca(2+) influx is coupled to calmodulin and calcineurin signaling and activation of NFAT-dependent transcriptional responses","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13469/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NFATC2","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NFATC2","total_profiled":1310},"omim":[{"mim_id":"620232","title":"JOINT CONTRACTURES, OSTEOCHONDROMAS, AND B-CELL LYMPHOMA; JCOSL","url":"https://www.omim.org/entry/620232"},{"mim_id":"617514","title":"IMMUNODEFICIENCY 52; IMD52","url":"https://www.omim.org/entry/617514"},{"mim_id":"615332","title":"INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN 2; IRF2BP2","url":"https://www.omim.org/entry/615332"},{"mim_id":"614525","title":"NFATC2-INTERACTING PROTEIN; NFATC2IP","url":"https://www.omim.org/entry/614525"},{"mim_id":"613146","title":"MICRO RNA 184; MIR184","url":"https://www.omim.org/entry/613146"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NFATC2"},"hgnc":{"alias_symbol":["NF-ATP","NFATp","NFAT1"],"prev_symbol":[]},"alphafold":{"accession":"Q13469","domains":[{"cath_id":"2.60.40.340","chopping":"405-569","consensus_level":"high","plddt":92.1206,"start":405,"end":569},{"cath_id":"2.60.40.10","chopping":"580-677","consensus_level":"high","plddt":95.079,"start":580,"end":677}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13469","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13469-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13469-F1-predicted_aligned_error_v6.png","plddt_mean":56.72},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFATC2","jax_strain_url":"https://www.jax.org/strain/search?query=NFATC2"},"sequence":{"accession":"Q13469","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13469.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13469/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13469"}},"corpus_meta":[{"pmid":"8397339","id":"PMC_8397339","title":"The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8397339","citation_count":715,"is_preprint":false},{"pmid":"8235597","id":"PMC_8235597","title":"Isolation of the cyclosporin-sensitive T cell transcription factor NFATp.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8235597","citation_count":423,"is_preprint":false},{"pmid":"8612134","id":"PMC_8612134","title":"Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8612134","citation_count":376,"is_preprint":false},{"pmid":"7565732","id":"PMC_7565732","title":"Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565732","citation_count":316,"is_preprint":false},{"pmid":"8631904","id":"PMC_8631904","title":"Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8631904","citation_count":253,"is_preprint":false},{"pmid":"8552071","id":"PMC_8552071","title":"Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8552071","citation_count":219,"is_preprint":false},{"pmid":"11309414","id":"PMC_11309414","title":"Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway.","date":"2001","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11309414","citation_count":206,"is_preprint":false},{"pmid":"10620601","id":"PMC_10620601","title":"The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10620601","citation_count":163,"is_preprint":false},{"pmid":"8816436","id":"PMC_8816436","title":"Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8816436","citation_count":161,"is_preprint":false},{"pmid":"12093869","id":"PMC_12093869","title":"Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12093869","citation_count":150,"is_preprint":false},{"pmid":"12453415","id":"PMC_12453415","title":"NFATc2-mediated repression of cyclin-dependent kinase 4 expression.","date":"2002","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12453415","citation_count":144,"is_preprint":false},{"pmid":"7982959","id":"PMC_7982959","title":"The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7982959","citation_count":124,"is_preprint":false},{"pmid":"7650486","id":"PMC_7650486","title":"Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7650486","citation_count":123,"is_preprint":false},{"pmid":"12695501","id":"PMC_12695501","title":"Prostaglandin F2(alpha) stimulates growth of skeletal muscle cells via an NFATC2-dependent pathway.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12695501","citation_count":119,"is_preprint":false},{"pmid":"10788511","id":"PMC_10788511","title":"A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10788511","citation_count":117,"is_preprint":false},{"pmid":"11740499","id":"PMC_11740499","title":"NFATc2 and NFATc3 regulate T(H)2 differentiation and modulate TCR-responsiveness of naïve T(H)cells.","date":"2001","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11740499","citation_count":115,"is_preprint":false},{"pmid":"7961754","id":"PMC_7961754","title":"Expression of the transcription factor NFATp in a neuronal cell line and in the murine nervous system.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7961754","citation_count":114,"is_preprint":false},{"pmid":"7891702","id":"PMC_7891702","title":"Human granulocyte-macrophage colony-stimulating factor enhancer function is associated with cooperative interactions between AP-1 and NFATp/c.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7891702","citation_count":114,"is_preprint":false},{"pmid":"19332646","id":"PMC_19332646","title":"RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.","date":"2009","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/19332646","citation_count":109,"is_preprint":false},{"pmid":"12355451","id":"PMC_12355451","title":"NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12355451","citation_count":105,"is_preprint":false},{"pmid":"7545680","id":"PMC_7545680","title":"Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7545680","citation_count":105,"is_preprint":false},{"pmid":"8668212","id":"PMC_8668212","title":"T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8668212","citation_count":101,"is_preprint":false},{"pmid":"8576111","id":"PMC_8576111","title":"Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp).","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8576111","citation_count":89,"is_preprint":false},{"pmid":"12949493","id":"PMC_12949493","title":"Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element.","date":"2003","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/12949493","citation_count":87,"is_preprint":false},{"pmid":"27013197","id":"PMC_27013197","title":"NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27013197","citation_count":83,"is_preprint":false},{"pmid":"7657645","id":"PMC_7657645","title":"Phosphorylation of the transcription factor NFATp inhibits its DNA binding activity in cyclosporin A-treated human B and T cells.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7657645","citation_count":83,"is_preprint":false},{"pmid":"22986745","id":"PMC_22986745","title":"Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22986745","citation_count":83,"is_preprint":false},{"pmid":"22079596","id":"PMC_22079596","title":"Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer.","date":"2011","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22079596","citation_count":77,"is_preprint":false},{"pmid":"31078563","id":"PMC_31078563","title":"EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review.","date":"2019","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31078563","citation_count":76,"is_preprint":false},{"pmid":"28583823","id":"PMC_28583823","title":"Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.","date":"2017","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/28583823","citation_count":74,"is_preprint":false},{"pmid":"21452283","id":"PMC_21452283","title":"Nfat1 regulates adult articular chondrocyte function through its age-dependent expression mediated by epigenetic histone methylation.","date":"2011","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/21452283","citation_count":73,"is_preprint":false},{"pmid":"25987655","id":"PMC_25987655","title":"Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25987655","citation_count":70,"is_preprint":false},{"pmid":"15684054","id":"PMC_15684054","title":"NFATc2 and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15684054","citation_count":68,"is_preprint":false},{"pmid":"33055242","id":"PMC_33055242","title":"LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33055242","citation_count":68,"is_preprint":false},{"pmid":"19286996","id":"PMC_19286996","title":"microRNA 184 regulates expression of NFAT1 in umbilical cord blood CD4+ T cells.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19286996","citation_count":67,"is_preprint":false},{"pmid":"24248346","id":"PMC_24248346","title":"NFATc1 and NFATc2 repress spontaneous osteoarthritis.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24248346","citation_count":67,"is_preprint":false},{"pmid":"19258413","id":"PMC_19258413","title":"Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19258413","citation_count":65,"is_preprint":false},{"pmid":"31972596","id":"PMC_31972596","title":"NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31972596","citation_count":64,"is_preprint":false},{"pmid":"10330159","id":"PMC_10330159","title":"A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10330159","citation_count":64,"is_preprint":false},{"pmid":"7583146","id":"PMC_7583146","title":"Only one of the two DNA-bound orientations of AP-1 found in solution cooperates with NFATp.","date":"1995","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/7583146","citation_count":63,"is_preprint":false},{"pmid":"12963831","id":"PMC_12963831","title":"Cell fusion in skeletal muscle--central role of NFATC2 in regulating muscle cell size.","date":"2003","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/12963831","citation_count":62,"is_preprint":false},{"pmid":"7722411","id":"PMC_7722411","title":"NFATp, a cyclosporin-sensitive transcription factor implicated in cytokine gene induction.","date":"1995","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/7722411","citation_count":61,"is_preprint":false},{"pmid":"30895378","id":"PMC_30895378","title":"DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma.","date":"2019","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30895378","citation_count":60,"is_preprint":false},{"pmid":"31049020","id":"PMC_31049020","title":"EWSR1-NFATC2 and FUS-NFATC2 Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review.","date":"2019","source":"Sarcoma","url":"https://pubmed.ncbi.nlm.nih.gov/31049020","citation_count":57,"is_preprint":false},{"pmid":"16027109","id":"PMC_16027109","title":"NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16027109","citation_count":57,"is_preprint":false},{"pmid":"36835440","id":"PMC_36835440","title":"Gsmtx4 Alleviated Osteoarthritis through Piezo1/Calcineurin/NFAT1 Signaling Axis under Excessive Mechanical Strain.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36835440","citation_count":56,"is_preprint":false},{"pmid":"22787160","id":"PMC_22787160","title":"Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22787160","citation_count":54,"is_preprint":false},{"pmid":"23762456","id":"PMC_23762456","title":"NFAT1 is highly expressed in, and regulates the invasion of, glioblastoma multiforme cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23762456","citation_count":54,"is_preprint":false},{"pmid":"29258522","id":"PMC_29258522","title":"NFAT1-regulated IL6 signalling contributes to aggressive phenotypes of glioma.","date":"2017","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/29258522","citation_count":53,"is_preprint":false},{"pmid":"21148038","id":"PMC_21148038","title":"Retinoic acid-induced CCR9 expression requires transient TCR stimulation and cooperativity between NFATc2 and the retinoic acid receptor/retinoid X receptor complex.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21148038","citation_count":52,"is_preprint":false},{"pmid":"30217928","id":"PMC_30217928","title":"Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30217928","citation_count":51,"is_preprint":false},{"pmid":"28737489","id":"PMC_28737489","title":"NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28737489","citation_count":51,"is_preprint":false},{"pmid":"23028325","id":"PMC_23028325","title":"Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCγ1 and activating NFAT1-dependent RCAN1 expression.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/23028325","citation_count":50,"is_preprint":false},{"pmid":"32991339","id":"PMC_32991339","title":"FUS-NFATC2 or EWSR1-NFATC2 Fusions Are Present in a Large Proportion of Simple Bone Cysts.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32991339","citation_count":49,"is_preprint":false},{"pmid":"29626598","id":"PMC_29626598","title":"EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29626598","citation_count":49,"is_preprint":false},{"pmid":"30467308","id":"PMC_30467308","title":"Upregulation of Ets1 expression by NFATc2 and NFKB1/RELA promotes breast cancer cell invasiveness.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30467308","citation_count":49,"is_preprint":false},{"pmid":"31181320","id":"PMC_31181320","title":"MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31181320","citation_count":46,"is_preprint":false},{"pmid":"35892263","id":"PMC_35892263","title":"NFAT1 Orchestrates Spinal Microglial Transcription and Promotes Microglial Proliferation via c-MYC Contributing to Nerve Injury-Induced Neuropathic Pain.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35892263","citation_count":42,"is_preprint":false},{"pmid":"22718120","id":"PMC_22718120","title":"NFATc2 is a potential therapeutic target in human melanoma.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22718120","citation_count":42,"is_preprint":false},{"pmid":"26823495","id":"PMC_26823495","title":"GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26823495","citation_count":41,"is_preprint":false},{"pmid":"23105117","id":"PMC_23105117","title":"Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23105117","citation_count":41,"is_preprint":false},{"pmid":"26387540","id":"PMC_26387540","title":"NFATc2 is an intrinsic regulator of melanoma dedifferentiation.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26387540","citation_count":39,"is_preprint":false},{"pmid":"25735562","id":"PMC_25735562","title":"NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer.","date":"2015","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25735562","citation_count":39,"is_preprint":false},{"pmid":"33754043","id":"PMC_33754043","title":"FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33754043","citation_count":39,"is_preprint":false},{"pmid":"30710146","id":"PMC_30710146","title":"An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30710146","citation_count":37,"is_preprint":false},{"pmid":"30940662","id":"PMC_30940662","title":"NFAT1-Mediated Regulation of NDEL1 Promotes Growth and Invasion of Glioma Stem-like Cells.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30940662","citation_count":36,"is_preprint":false},{"pmid":"33316098","id":"PMC_33316098","title":"Identification of EWSR1-NFATC2 fusion in simple bone cysts.","date":"2021","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/33316098","citation_count":35,"is_preprint":false},{"pmid":"35081978","id":"PMC_35081978","title":"A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35081978","citation_count":35,"is_preprint":false},{"pmid":"23583303","id":"PMC_23583303","title":"The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF-α expression.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23583303","citation_count":35,"is_preprint":false},{"pmid":"9653115","id":"PMC_9653115","title":"Molecular basis of cooperative DNA bending and oriented heterodimer binding in the NFAT1-Fos-Jun-ARRE2 complex.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9653115","citation_count":34,"is_preprint":false},{"pmid":"33179105","id":"PMC_33179105","title":"PDGF mediates pulmonary arterial smooth muscle cell proliferation and migration by regulating NFATc2.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33179105","citation_count":34,"is_preprint":false},{"pmid":"15347678","id":"PMC_15347678","title":"Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15347678","citation_count":33,"is_preprint":false},{"pmid":"12374807","id":"PMC_12374807","title":"Identification of three NFAT binding motifs in the 5'-upstream region of the human CD3gamma gene that differentially bind NFATc1, NFATc2, and NF-kappa B p50.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12374807","citation_count":33,"is_preprint":false},{"pmid":"35773432","id":"PMC_35773432","title":"Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35773432","citation_count":32,"is_preprint":false},{"pmid":"31181312","id":"PMC_31181312","title":"miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31181312","citation_count":32,"is_preprint":false},{"pmid":"22865456","id":"PMC_22865456","title":"NFAT1 supports tumor-induced anergy of CD4(+) T cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22865456","citation_count":32,"is_preprint":false},{"pmid":"7842733","id":"PMC_7842733","title":"Cloning and chromosomal localization of the human and murine genes for the T-cell transcription factors NFATc and NFATp.","date":"1995","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7842733","citation_count":30,"is_preprint":false},{"pmid":"34311033","id":"PMC_34311033","title":"TRPC3 promotes tumorigenesis of gastric cancer via the CNB2/GSK3β/NFATc2 signaling pathway.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34311033","citation_count":30,"is_preprint":false},{"pmid":"25630465","id":"PMC_25630465","title":"NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25630465","citation_count":29,"is_preprint":false},{"pmid":"32537408","id":"PMC_32537408","title":"LncRNA UCA1 Antagonizes Arsenic-Induced Cell Cycle Arrest through Destabilizing EZH2 and Facilitating NFATc2 Expression.","date":"2020","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/32537408","citation_count":28,"is_preprint":false},{"pmid":"34036377","id":"PMC_34036377","title":"Propofol maintains Th17/Treg cell balance and reduces inflammation in rats with traumatic brain injury via the miR‑145‑3p/NFATc2/NF‑κB axis.","date":"2021","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34036377","citation_count":28,"is_preprint":false},{"pmid":"38289255","id":"PMC_38289255","title":"An NFAT1-C3a-C3aR Positive Feedback Loop in Tumor-Associated Macrophages Promotes a Glioma Stem Cell Malignant Phenotype.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/38289255","citation_count":27,"is_preprint":false},{"pmid":"32840323","id":"PMC_32840323","title":"Testicular Lmcd1 regulates phagocytosis by Sertoli cells through modulation of NFAT1/Txlna signaling pathway.","date":"2020","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/32840323","citation_count":26,"is_preprint":false},{"pmid":"26461225","id":"PMC_26461225","title":"Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26461225","citation_count":25,"is_preprint":false},{"pmid":"35286582","id":"PMC_35286582","title":"SOCE-mediated NFAT1-NOX2-NLRP1 inflammasome involves in lipopolysaccharide-induced neuronal damage and Aβ generation.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/35286582","citation_count":24,"is_preprint":false},{"pmid":"16849457","id":"PMC_16849457","title":"Involvement of NFAT1 in B cell self-tolerance.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16849457","citation_count":24,"is_preprint":false},{"pmid":"19060202","id":"PMC_19060202","title":"A dimer-specific function of the transcription factor NFATp.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19060202","citation_count":23,"is_preprint":false},{"pmid":"27859969","id":"PMC_27859969","title":"FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells.","date":"2016","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/27859969","citation_count":23,"is_preprint":false},{"pmid":"34491912","id":"PMC_34491912","title":"Identification of direct transcriptional targets of NFATC2 that promote β cell proliferation.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34491912","citation_count":23,"is_preprint":false},{"pmid":"25550437","id":"PMC_25550437","title":"NFATc2 mediates epigenetic modification of dendritic cell cytokine and chemokine responses to dectin-1 stimulation.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25550437","citation_count":23,"is_preprint":false},{"pmid":"38448411","id":"PMC_38448411","title":"The RNA m6A reader IGF2BP3 regulates NFAT1/IRF1 axis-mediated anti-tumor activity in gastric cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38448411","citation_count":22,"is_preprint":false},{"pmid":"30828328","id":"PMC_30828328","title":"NFAT1 and NFAT2 Differentially Regulate CTL Differentiation Upon Acute Viral Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30828328","citation_count":22,"is_preprint":false},{"pmid":"34168481","id":"PMC_34168481","title":"LRRK2-NFATc2 Pathway Associated with Neuroinflammation May Be a Potential Therapeutic Target for Parkinson's Disease.","date":"2021","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/34168481","citation_count":22,"is_preprint":false},{"pmid":"21964595","id":"PMC_21964595","title":"Negative cross talk between NFAT1 and Stat5 signaling in breast cancer.","date":"2011","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21964595","citation_count":21,"is_preprint":false},{"pmid":"30294794","id":"PMC_30294794","title":"Invasion and migration of MDA-MB-231 cells are inhibited by block of AhR and NFAT: role of AhR/NFAT1/β4 integrin signaling.","date":"2018","source":"Journal of applied toxicology : JAT","url":"https://pubmed.ncbi.nlm.nih.gov/30294794","citation_count":20,"is_preprint":false},{"pmid":"29969451","id":"PMC_29969451","title":"Activation of Th2 cells downregulates CRTh2 through an NFAT1 mediated mechanism.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29969451","citation_count":19,"is_preprint":false},{"pmid":"32515123","id":"PMC_32515123","title":"OSW-1 inhibits tumor growth and metastasis by NFATc2 on triple-negative breast cancer.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32515123","citation_count":18,"is_preprint":false},{"pmid":"32339381","id":"PMC_32339381","title":"CD147 regulates melanoma metastasis via the NFAT1-MMP-9 pathway.","date":"2020","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/32339381","citation_count":17,"is_preprint":false},{"pmid":"27399331","id":"PMC_27399331","title":"NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/27399331","citation_count":17,"is_preprint":false},{"pmid":"23110116","id":"PMC_23110116","title":"NFAT1 C-terminal domains are necessary but not sufficient for inducing cell death.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23110116","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51347,"output_tokens":11176,"usd":0.16084,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22095,"output_tokens":7021,"usd":0.143,"stage2_stop_reason":"end_turn"},"total_usd":0.30384,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"NFATp (NFATC2) is a DNA-binding phosphoprotein that is a direct substrate for the phosphatase calcineurin in vitro, and forms a ternary complex with Fos and Jun proteins on composite DNA elements; the DNA-binding domains of Fos and Jun are required for NFATp-Fos-Jun-DNA complex formation.\",\n      \"method\": \"In vitro calcineurin phosphatase assay with purified NFATp; recombinant protein DNA-binding assays with Fos/Jun; mutagenesis of Fos/Jun DNA-binding domains\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of calcineurin-substrate relationship, direct protein-DNA and protein-protein interaction assays, replicated across multiple studies\",\n      \"pmids\": [\"8397339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NFATp is the DNA-binding subunit of the NFAT transcription complex; a recombinant truncated form binds specifically to the NFAT site of the murine IL-2 promoter and forms a transcriptionally active complex.\",\n      \"method\": \"Protein purification from murine T cells; cDNA cloning; recombinant protein DNA-binding assay; reporter transcription assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical reconstitution of DNA binding and transcriptional activity, multiple orthogonal methods\",\n      \"pmids\": [\"8235597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Phosphorylation of NFATp inhibits its DNA-binding activity and its ability to form an NFAT complex with Fos and Jun; dephosphorylation by calcineurin or alkaline phosphatase in vitro restores DNA binding and complex formation with Fos/Jun.\",\n      \"method\": \"Immunoblot, 32P metabolic labeling, in vitro calcineurin/alkaline phosphatase treatment, EMSA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical demonstration of phosphorylation-dependent DNA binding, multiple orthogonal methods\",\n      \"pmids\": [\"7657645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"NFATp undergoes calcineurin-dependent dephosphorylation and nuclear translocation upon ionomycin stimulation in T cells; immunoprecipitated NFATp from unstimulated cells is dephosphorylated by calcineurin in vitro, confirming it is an in vitro calcineurin substrate.\",\n      \"method\": \"Subcellular fractionation, Western blot, immunoprecipitation, 32P labeling, in vitro calcineurin dephosphorylation assay, FK506 inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct in vitro substrate assay combined with cellular fractionation, replicated finding across multiple labs\",\n      \"pmids\": [\"7545680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"NFAT1 (NFATp/NFATC2) directly interacts with calcineurin through an N-terminal region conserved among NFAT family members; both phosphorylated and dephosphorylated forms of NFATp bind calcineurin, and this binding is blocked by the FK506-FKBP12 complex.\",\n      \"method\": \"Pulldown of NFATp from T cell lysates on immobilized calcineurin; inhibition with FK506-FKBP12 complex\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct physical interaction demonstrated, replicated by independent lab (PMID 8631904), FK506-FKBP12 competition control\",\n      \"pmids\": [\"8576111\", \"8631904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Calcineurin activity levels directly control the activation state of NFAT1: cessation of calcium signaling (EGTA, ionomycin removal) or addition of cyclosporin A causes rapid rephosphorylation of NFAT1 and its re-export to the cytoplasm, reversing nuclear accumulation and DNA binding.\",\n      \"method\": \"Subcellular fractionation, Western blot, cyclosporin A/EGTA/ionomycin pharmacological manipulation in T cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple pharmacological interventions, reciprocal reversibility demonstrated, consistent with calcineurin-substrate relationship\",\n      \"pmids\": [\"8631904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"NFATp binds to two sites within the κ3 element of the TNF-α promoter, and occupancy of both sites is required for calcium-stimulated, cyclosporin A-sensitive TNF-α gene induction in T cells.\",\n      \"method\": \"EMSA, promoter-reporter assays, cyclosporin A inhibition, site mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct DNA-binding and promoter functional assays with site-specific mutagenesis\",\n      \"pmids\": [\"7982959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"NFATp cooperates with ATF-2/Jun bound to an adjacent CRE site for TNF-α gene transcription in T cells; ATF-2 and Jun bind noncooperatively with NFATp in vitro, but the composite CRE/κ3 site shows dramatically higher transcriptional activity than κ3 alone, indicating in vivo cooperation.\",\n      \"method\": \"EMSA, promoter-reporter assays, T cell stimulation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct DNA-binding and transcriptional assays, functional in vivo cooperation demonstrated\",\n      \"pmids\": [\"8552071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"On the GM-CSF enhancer composite elements, NFATp and AP-1 bind cooperatively, and this cooperativity requires a specific spacing (9 bp) between GGA and TCA motifs; a site with 15 bp spacing supports strong independent but no cooperative binding of AP-1 and NFATp and functions poorly as an enhancer.\",\n      \"method\": \"EMSA, methylation interference, DNase footprinting, reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical and functional dissection with quantitative spacing analysis, multiple methods\",\n      \"pmids\": [\"7891702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"In the cooperative NFAT-AP-1 complex on the IL-2 ARRE2 element, AP-1 (Fos-Jun) adopts a single orientation (Jun proximal, Fos distal to NFATp) through protein-protein contacts; in solution AP-1 binds as a mixture of orientational isomers, but NFATp locks a single orientation.\",\n      \"method\": \"Affinity cleaving experiments, protein cross-linking, EMSA\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with affinity-cleaving and cross-linking to define orientation, single lab\",\n      \"pmids\": [\"7583146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The vitamin D receptor (VDR) directly competes with NFATp/AP-1 complex formation at the NF-AT-1 element of the IL-2 promoter; VDR-RXR heterodimer blocks NFATp/AP-1 complex formation and stably associates with the NF-AT-1 element; VDR DNA-binding is necessary but not sufficient for repression.\",\n      \"method\": \"In vitro competition assays with partially purified proteins, order-of-addition and off-rate experiments, cotransfection reporter assays, VDR DNA-binding domain mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted competition in vitro with purified proteins, in vivo mutagenesis validation, single lab\",\n      \"pmids\": [\"7565732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"VDR competes with NFAT1 for binding to the GM-CSF NFAT-AP-1 composite site; overexpression of NFAT1 relieves VDR-dependent repression; VDR also directly interacts with c-Jun (demonstrated by GST coprecipitation) and stabilizes Jun-Fos binding adjacent to the NFAT1 binding site, providing a two-hit inhibitory mechanism.\",\n      \"method\": \"Transient transfection reporter assays, EMSA competition, GST coprecipitation, FLAG-VDR immunoprecipitation from nuclear extracts\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reconstituted competition, direct protein-protein interaction by GST pulldown, in vivo rescue experiments\",\n      \"pmids\": [\"10330159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TCR stimulation leads to rapid (<minutes) calcineurin-dependent dephosphorylation, nuclear translocation, and increased DNA binding of NFAT1, followed hours later by phorbol ester-facilitated rephosphorylation and cytoplasmic re-export; late deactivation is facilitated by PKC-dependent pathways and inhibitors of capacitative calcium entry.\",\n      \"method\": \"Subcellular fractionation, EMSA, Western blot, pharmacological inhibition (cyclosporin A, PMA, ionomycin, EGTA)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods, temporal dissection of activation/deactivation cycle\",\n      \"pmids\": [\"8668212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"p38 MAPK phosphorylates NFATp in vitro and interacts with NFATp in vivo; activation of p38 (via MKK6) counteracts calcium-induced nuclear accumulation of NFATp (but not NFATc) and inhibits NFATp-driven transcription; p38-mediated nuclear export of NFATp is CRM1-dependent (Leptomycin B-sensitive).\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, cotransfection with activated MKK6/p38, nuclear/cytoplasmic fractionation, Leptomycin B treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro phosphorylation assay combined with cell-based fractionation and pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"10788511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of NFAT1 (NFATC2) bound as a dimer to the HIV-1 LTR κB element reveals a novel asymmetric dimerization mode through the C-terminal Rel homology subdomain, distinct from other Rel family dimers; both N- and C-terminal subdomains form protein-protein contacts encircling the DNA.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure, high-resolution direct structural determination\",\n      \"pmids\": [\"12949493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NFAT1 induces cooperative DNA bending at the ARRE2 site in the NFAT1-Fos-Jun ternary complex that differs from the sum of individual bends; NFAT1 interaction with the Fos-Jun leucine zipper (specifically three N-terminal residues) can reverse the orientation of Fos-Jun heterodimer binding on DNA.\",\n      \"method\": \"Gel electrophoretic phasing analysis, fluorescence resonance energy transfer (FRET) orientation assay, mutagenesis of Fos/Jun leucine zippers\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple biophysical and structural methods in one study, site-directed mutagenesis validation\",\n      \"pmids\": [\"9653115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NFATp dimerization on the TNF promoter NFAT-bZIP element creates a dimer-specific function: the NFATp dimer and its bZIP partner bind noncooperatively to this element, whereas a monomer recruits bZIP cooperatively; NFATp dimer-specific activation subdomains interact with the coactivator CBP and are required for transcriptional activation from the TNF element.\",\n      \"method\": \"Consensus binding site determination, DNase footprinting, transcriptional reporter assays, coactivator interaction assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple biochemical and functional methods, structure-function mapping, CBP interaction demonstrated\",\n      \"pmids\": [\"19060202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NFATC2 is required intrinsically for skeletal muscle cell growth: NFATC2-null primary myotubes show reduced size and myonuclear number; retroviral re-expression of NFATC2 rescues these defects; NFATC2 controls a second phase of myoblast fusion (nuclear accretion) after initial myotube formation.\",\n      \"method\": \"NFATC2 knockout mouse analysis, primary muscle cell culture, retroviral rescue, morphometric measurement of myotube size and nuclear number\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined cellular phenotype, retroviral rescue, multiple readouts\",\n      \"pmids\": [\"11309414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Prostaglandin F2α (PGF2α) stimulates skeletal muscle cell growth through the FP receptor and requires NFATC2 activation: PGF2α activates NFAT, and NFATC2-null myotubes fail to grow or accrue nuclei in response to PGF2α, identifying the first intersection between prostaglandin receptor signaling and NFAT.\",\n      \"method\": \"PGF2α/analogue treatment of primary muscle cultures, NFAT reporter assay, NFATC2 knockout myotubes, nuclear accretion counts\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined pathway and phenotypic readout, pharmacological receptor activation\",\n      \"pmids\": [\"12695501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"NFATp (NFATC2) functions as a repressor of chondrogenesis in vivo: mice lacking NFATp spontaneously develop cartilage from extraarticular connective tissue, and NFATp overexpression in cartilage cell lines extinguishes the cartilage phenotype; NFATp expression is regulated during mesenchymal stem cell chondrogenic differentiation.\",\n      \"method\": \"NFATp knockout mouse histology, overexpression in chondrocyte cell lines, cartilage marker expression analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with spontaneous phenotype, confirmed by overexpression in cell lines, multiple readouts\",\n      \"pmids\": [\"10620601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NFATc2 negatively regulates CDK4 expression by binding a canonical NFAT site in the CDK4 promoter in a calcium-sensitive, FK506/CsA-sensitive, and histone deacetylase-sensitive manner; ectopic NFATc2 inhibits CDK4 promoter activity; calcineurin Aα−/− and NFATc2−/− mice have elevated CDK4 protein levels.\",\n      \"method\": \"Promoter-reporter assays, pharmacological inhibition (FK506, CsA, HDAC inhibitors), NFATc2 overexpression, Western blot of CDK4 in KO mice\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — promoter binding demonstrated, confirmed in two independent KO mouse models, multiple pharmacological validations\",\n      \"pmids\": [\"12453415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-6 upregulates NFATc2 protein levels in CD4+ T cells, increasing NFAT transcriptional activity, which drives IL-4 production; CD4+ T cells lacking NFATc2 fail to produce IL-4 in response to IL-6, preventing Th2 differentiation.\",\n      \"method\": \"NFATc2 knockout CD4+ T cells, IL-6 stimulation, IL-4 ELISA, NFAT transcriptional reporter, cyclosporin A inhibition\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined molecular and cellular phenotype, NFAT reporter confirmation\",\n      \"pmids\": [\"12093869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NFAT1 (NFATc2) and NFAT2 are both positive regulators of IL-4 gene transcription when constitutively active (Ala substitution) forms are expressed; the disparate knockout phenotypes reflect differential regulation of the two proteins rather than intrinsic differences in DNA binding or transcriptional activity at the IL-4 locus.\",\n      \"method\": \"Constitutively active (phospho-Ser→Ala) mutant NFAT overexpression, IL-4 reporter and secretion assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with defined mutants, single lab, two methods\",\n      \"pmids\": [\"12355451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NFATc2 directly binds the IL-21 proximal promoter and activates its transcription in Th2 cells; T-bet represses IL-21 transcription in Th1 cells by inhibiting NFATc2 binding to the IL-21 promoter.\",\n      \"method\": \"Promoter-reporter assays, chromatin immunoprecipitation (ChIP), EMSA, T-bet overexpression/NFATc2 competition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP, EMSA, and functional reporter assays, T-bet competition mechanism defined\",\n      \"pmids\": [\"15684054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GSK-3β mediates inhibition of NFAT (including NFAT1) activity downstream of Akt1; GSK-3β-dependent NFAT inhibition leads to proteasomal degradation of NFAT and blocks breast cancer cell migration; GSK-3β mutants unresponsive to Akt reveal that Akt-mediated inhibition of migration is mediated through GSK-3β.\",\n      \"method\": \"GSK-3β shRNA and selective inhibitor, GSK-3β mutants unresponsive to Akt, NFAT reporter, proteasome inhibitor assays, migration assay\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological approaches, proteasomal degradation pathway defined, single lab\",\n      \"pmids\": [\"19258413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NFATc2 in pancreatic cancer cells targets the p15(INK4b) promoter and induces heterochromatin formation through sequential recruitment of histone methyltransferase Suv39H1, H3K9 trimethylation, and HP1γ docking; inactivation of NFATc2 disrupts this repressor complex, restoring p15(INK4b) expression and inhibiting cancer growth.\",\n      \"method\": \"ChIP, co-immunoprecipitation, DNA pulldown, reporter assays, xenograft tumor models, H3K9me3 ChIP\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ChIP, co-IP, functional reporter), confirmed in vivo in xenograft model\",\n      \"pmids\": [\"22079596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NFAT1 (NFATC2) directly binds the mdm2 P2 promoter in vitro and in vivo and upregulates MDM2 transcription; enforced NFAT1 expression elevates MDM2 protein and reduces p53 function after DNA damage.\",\n      \"method\": \"EMSA, ChIP, reporter assays, NFAT1 overexpression, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct EMSA and ChIP for promoter binding, functional gain-of-function, multiple methods\",\n      \"pmids\": [\"22787160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"VRK2 directly interacts with and phosphorylates NFAT1 at Ser-32 within its N-terminal transactivation domain; this phosphorylation by VRK2 increases NFAT1-dependent transcription and COX-2 expression through the NFAT1 binding site in the COX-2 promoter, promoting tumor cell invasion.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, luciferase reporter with COX-2 promoter, VRK2 RNAi, invasion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay identifying phosphorylation site (Ser-32), functional reporter and cellular invasion assay\",\n      \"pmids\": [\"23105117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LRRK2 kinase selectively phosphorylates NFATc2 and induces its nuclear translocation in microglia; α-synuclein activates LRRK2, which phosphorylates NFATc2 to drive neuroinflammatory TNF-α and IL-6 expression; genetic or pharmacological LRRK2 inhibition reduces NFATc2 nuclear translocation and microglial neurotoxicity.\",\n      \"method\": \"Primary mouse microglia cultures, LRRK2 genetic knockout/pharmacological inhibition, nuclear fractionation, cytokine ELISA, in vivo synucleinopathy mouse model\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway with genetic and pharmacological validation, confirmed in vivo, published in Science Translational Medicine\",\n      \"pmids\": [\"33055242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GSK-3β phosphorylates NFATc2 at SP2 motif to stabilize NFATc2 protein in the nucleus of pancreatic cancer cells; additionally, GSK-3β maintains NFATc2 activation through stabilization of NFATc2-STAT3 complexes via GSK-3β-mediated STAT3 phosphorylation at Y705, stimulating euchromatin formation at NFATc2 target promoters such as CDK6.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, reporter assay, GSK-3β inhibition/activation, xenograft and GEMM models\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP and ChIP for complex formation, functional readouts in multiple in vivo models, mechanistic detail at phosphorylation site level\",\n      \"pmids\": [\"26823495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NFAT1 (NFATC2) directly regulates IL8 and MMP3 transcription in melanoma cells to promote tumor growth and lung metastasis; silencing NFAT1 reduces IL8 and MMP3 expression, and restoration rescues expression to baseline; both genes are validated as direct transcriptional targets by rescue experiments.\",\n      \"method\": \"NFAT1 stable silencing, microarray, qRT-PCR, overexpression rescue, in vivo xenograft/metastasis assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with rescue, in vivo validation, but no direct ChIP shown in abstract\",\n      \"pmids\": [\"27013197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NFATc2 directly binds two NFAT-binding sites in the 5'-flanking region of the mouse Ccr9 gene and cooperates with the RAR/RXR complex bound to an adjacent RA response element half-site to drive CCR9 expression; NFATc2 enhances RARα binding to the RA response element; NFATc1, though it also binds the same sites and RARα/RXRα, inhibits NFATc2-dependent promoter activity.\",\n      \"method\": \"Reporter assays, DNA-affinity precipitation, direct protein interaction assay, murine naive CD4+ T cells, cyclosporin A inhibition\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct DNA binding, protein-protein interaction, and functional reporter assays, detailed mechanistic dissection\",\n      \"pmids\": [\"21148038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NFATC2 induces β cell proliferation and activates ~2200 transcriptional targets in human islets; NFATC2 response elements in the SOX2 3' enhancer and ALDH1A1 5' enhancer are identified; NFATC2 induces Nr4a1, which is required for much of the proliferative effect; FOXP family transcription factors cooperate with NFATC2 to regulate β cell proliferation.\",\n      \"method\": \"Active NFATC2 expression in human islets, RNA-seq, ChIP-seq, FOXP1/2/4 triple KO islets, Nr4a1 deletion, ATAC-seq\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — integrated genomics (ChIP-seq + RNA-seq + ATAC-seq), genetic validation with KO models, multiple orthogonal methods\",\n      \"pmids\": [\"34491912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFATc2 mediates epigenetic modification of DC cytokine and chemokine gene loci in response to dectin-1 stimulation; genome-wide NFATc2 binding (ChIP-seq) reveals occupancy at cytokine/chemokine loci, and NFATc2 binding is required to induce the H3K4me3 activating histone mark at these loci.\",\n      \"method\": \"ChIP-seq for NFATc2 genome-wide binding, H3K4me3 ChIP, gene expression profiling, dectin-1 stimulation of DCs\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq, epigenetic mark validated by ChIP, comprehensive gene expression integration\",\n      \"pmids\": [\"25550437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Dapl1 restrains NFATc2 activation in CD8+ T cells; Dapl1 deficiency enhances NFATc2 activation, improving effector function and preventing exhaustion; exhausted CD8+ T cells display attenuated NFATc2 activation due to Tim3-mediated feedback inhibition, which Dapl1 deletion rescues.\",\n      \"method\": \"Dapl1 KO mice, T cell adoptive transfer, NFATc2 reporter/activation assay, Tim3 feedback inhibition analysis, tumor models\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with mechanistic pathway defined, multiple in vivo models, published in Nature Cell Biology\",\n      \"pmids\": [\"35773432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NFATc2 binds the 3' enhancer region of SOX2, coupling NFATc2/SOX2 to upregulate ALDH1A1 via its 5' enhancer; this NFATc2/SOX2/ALDH1A1 axis attenuates oxidative stress from cancer drug treatment, promoting drug resistance in lung cancer tumor-initiating cells.\",\n      \"method\": \"NFATc2 KD/OE, reporter assays, ChIP for NFATc2 binding to SOX2 and ALDH1A1 enhancers, sphere formation and in vivo tumorigenesis assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter validation of binding, functional rescue, single lab\",\n      \"pmids\": [\"28737489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NFAT1 directly binds the MMP-9 promoter in melanoma cells and drives MMP-9 expression; CD147 activates NFAT1 via the intracellular Ca2+-calcineurin pathway; knockdown of NFAT1 suppresses melanoma metastasis in an NFAT1-dependent manner; CD147 knockdown reduces NFAT1-MMP-9 promoter binding.\",\n      \"method\": \"Luciferase reporter with MMP-9 promoter, ChIP for NFAT1 at MMP-9 promoter, siRNA knockdown, Ca2+ signaling assays\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP and reporter assays for target binding, functional knockdown, single lab\",\n      \"pmids\": [\"32339381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FGF19/FGFR4 signaling activates store-operated Ca2+ entry (SOCE) via PLCγ and ERK1/2 pathways, which activates calcineurin and promotes NFATc2 nuclear translocation; nuclear NFATc2 transcriptionally activates stemness genes (NANOG, OCT4, SOX2) and FGF19 itself, creating a positive feedback loop sustaining liver cancer stem cell self-renewal.\",\n      \"method\": \"Ca2+ imaging, calcineurin activity assay, NFATc2 nuclear fractionation, ChIP for NFATc2 at stemness gene promoters, sphere assays, FGFR4 knockdown/overexpression\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct binding, Ca2+ and calcineurin activity assays, functional rescue, single lab\",\n      \"pmids\": [\"33754043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NFAT1 (NFATc2) directly binds to and activates the IL8 gene promoter in breast cancer cells, leading to IL8 secretion that promotes primary human neutrophil migration; NFAT1-mediated IL8 production is stimulated by thapsigargin and suppresses nascent tumor growth by a non-cell-autonomous mechanism.\",\n      \"method\": \"ChIP for NFAT1 at IL8 promoter, NFAT reporter, thapsigargin stimulation, neutrophil migration assay, xenograft tumor growth\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP showing promoter binding, functional in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"25735562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NFATc2 controls melanoma dedifferentiation by inducing expression of membrane-bound TNF-α (mTNF-α), which then regulates a c-Myc–Brn2 axis to suppress MITF and maintain a dedifferentiated state; NFATc2 silencing upregulates MITF, melanocyte differentiation antigens, and pigmentation.\",\n      \"method\": \"siRNA and shRNA silencing, NFATc2 inhibitor, TNF-α neutralization, c-Myc inhibition, Brn2 silencing, FACS, cytolytic T cell assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sequential pathway dissection by multiple knockdowns, but no direct ChIP for mTNF-α promoter shown in abstract\",\n      \"pmids\": [\"26387540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NFAT1 is upregulated in spinal microglia after nerve ligation via TET2-mediated DNA demethylation; NFAT1 directly binds promoters of Itgam, Tnf, Il-1b, and c-Myc in the spinal cord; NFAT1 promotes microglial proliferation through c-MYC; microglia-specific deletion of Nfat1 attenuates neuropathic pain.\",\n      \"method\": \"Microglia-specific Nfat1 KO mice, ChIP for NFAT1 binding, c-MYC overexpression, intrathecal siRNA injection, TET2/DNA methylation analysis\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP at multiple promoters, genetic KO with defined phenotype, single lab\",\n      \"pmids\": [\"35892263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NFAT1 physically interacts with Stat5 through Stat5's DNA-binding and transactivation domains; ectopic NFAT1 inhibits Stat5 transactivation, Stat5-mediated transcription, and Stat5a binding to its target promoter; conversely, Stat5 inhibits NFAT1 signaling, establishing mutual negative cross-talk.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter, ChIP for Stat5a, NFAT1 overexpression and RNAi, VIVIT (NFAT inhibitor) treatment\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and functional reporter assays, single lab\",\n      \"pmids\": [\"21964595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NFAT1 is required for B cell clonal anergy: NFAT1-deficient mice crossed with anti-lysozyme Ig transgenic/soluble lysozyme double transgenic mice show relief of B cell anergy, demonstrating that NFAT1 mediates peripheral B cell tolerance to self-antigen.\",\n      \"method\": \"NFAT1 KO mice crossed with double-transgenic anergy model, serum antibody levels, B cell numbers, proliferation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in defined anergy model, clean KO with specific phenotypic readout, single lab\",\n      \"pmids\": [\"16849457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NFAT1 mediates the induction of anergy-associated genes in CD4+ T cells in response to cancer antigen stimulation without costimulation; NFAT1-deficient antigen-specific CD4+ T cells show blunted anergy induction and enhanced anti-tumor responses in a murine melanoma model.\",\n      \"method\": \"NFAT1 KO mouse melanoma model, antigen-specific CD4+ T cell cytokine assays, NFAT1-deficient T cell transfer\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO in defined tumor-anergy model, specific mechanistic pathway placement, single lab\",\n      \"pmids\": [\"22865456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NFATc2 and NFKB1/RELA directly bind a core regulatory element (CRE, -540/-80 bp from TSS) in the Ets1 promoter to trans-activate Ets1 transcription in metastatic breast cancer cells; CRISPR/Cas9 deletion of the CRE reduces Ets1 expression and tumor invasiveness-related gene programs.\",\n      \"method\": \"ChIP for NFATc2 and NFKB1/RELA at Ets1 CRE, EMSA, CRISPR/Cas9 CRE deletion, reporter assays\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP and CRISPR genetic validation, functional transcriptional readout, single lab\",\n      \"pmids\": [\"30467308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-15 specifically recruits NFAT1 (but not NFAT2) to the κB-like NFAT site in the CX3CR1 promoter to repress CX3CR1 expression, while IL-2 recruits NFAT2 to activate CX3CR1; NFAT1-deficient mice fail to show IL-15-dependent CX3CR1 downregulation.\",\n      \"method\": \"ChIP for NFAT1/NFAT2 at CX3CR1 promoter, NFAT1 KO mice, NFAT inhibitors (CsA, VIVIT), mutation of κB-NFAT site, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP, genetic KO, pharmacological and mutation-based validation, consistent in vivo confirmation\",\n      \"pmids\": [\"15347678\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NFATC2 (NFATp/NFAT1) is a calcium/calcineurin-regulated transcription factor that resides in the cytoplasm in a hyperphosphorylated, DNA-binding-incompetent state; calcineurin dephosphorylates it directly, triggering nuclear translocation and activation of cytokine genes (IL-2, IL-4, IL-21, TNF-α, GM-CSF) through cooperative ternary complexes with Fos-Jun (AP-1) on composite NFAT-AP-1 elements; nuclear export is driven by rephosphorylation via kinases including p38 MAPK and GSK-3β (the latter also controlling proteasomal stability and STAT3 complex formation); the protein can also act as a transcriptional repressor (of CDK4, p15(INK4b), CX3CR1, Cyclin E, and chondrogenic genes) and structurally can function as both a monomer and asymmetric dimer on DNA, with dimer-specific activation subdomains recruiting the CBP coactivator; beyond immune cells, NFATC2 controls skeletal muscle growth (via IL-4 and prostaglandin F2α signaling), cartilage homeostasis, β-cell proliferation (through Nr4a1 and FOXP co-factors), and is aberrantly activated in multiple cancers where it drives targets including MDM2, MMP3, MMP-9, IL8, SOX2/ALDH1A1, and Ets1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NFATC2 (NFATp/NFAT1) is a calcium/calcineurin-regulated transcription factor that converts T-cell receptor and other Ca2+-mobilizing signals into programs of cytokine gene expression and broader cell-fate decisions [#1, #3]. In resting cells it is a hyperphosphorylated, DNA-binding-incompetent phosphoprotein; calcineurin binds NFATC2 directly through a conserved N-terminal region and dephosphorylates it, restoring DNA binding and driving nuclear accumulation, while cessation of Ca2+ signaling, cyclosporin A, or FK506-FKBP12 reverses these steps and re-exports the protein [#0, #2, #4, #5]. The activation cycle is closed by kinases that rephosphorylate NFATC2 to promote CRM1-dependent nuclear export and turnover: p38 MAPK opposes its nuclear accumulation [#13], and GSK-3\\u03b2 both targets NFAT for proteasomal degradation downstream of Akt [#24] and, paradoxically in pancreatic cancer, stabilizes nuclear NFATC2 and its STAT3 complexes to maintain target-gene chromatin in an active state [#29]. Once nuclear, NFATC2 acts as the DNA-binding subunit of composite enhancer complexes, cooperating with AP-1 (Fos-Jun) and ATF-2/Jun on spacing-constrained NFAT-AP-1 elements of IL-2, GM-CSF, and TNF-\\u03b1 promoters, where it locks AP-1 orientation and bends DNA through specific protein-protein contacts [#0, #7, #8, #9, #15]. Structurally it binds DNA as a monomer or as a novel asymmetric Rel-homology dimer, and the dimer form carries activation subdomains that recruit the CBP coactivator [#14, #16]. Through these complexes NFATC2 drives cytokine and effector genes (TNF-\\u03b1, IL-4, IL-21) and mediates T-cell anergy and B-cell tolerance [#6, #21, #23, #42, #43], and it also functions as a sequence-specific repressor, silencing CDK4 and the p15(INK4b) locus via Suv39H1/H3K9me3/HP1\\u03b3 heterochromatin assembly and repressing CX3CR1 [#20, #25, #45]. Beyond immunity, NFATC2 is intrinsically required for skeletal myotube growth and nuclear accretion downstream of prostaglandin F2\\u03b1/FP signaling [#17, #18], represses chondrogenesis [#19], and drives \\u03b2-cell proliferation through Nr4a1 and FOXP cofactors [#32]. In cancer it is aberrantly activated to transcribe MDM2, MMP3, MMP-9, IL8, the SOX2/ALDH1A1 stemness-and-drug-resistance axis, and Ets1, promoting invasion, metastasis, and tumor-initiating-cell self-renewal [#26, #30, #35, #36, #44].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the foundational identity of NFATC2 as the DNA-binding subunit of the NFAT complex and as a direct calcineurin substrate that builds ternary complexes with AP-1.\",\n      \"evidence\": \"Protein purification, cDNA cloning, recombinant DNA-binding and reporter assays, and in vitro calcineurin phosphatase assays with Fos/Jun DNA-binding-domain mutagenesis\",\n      \"pmids\": [\"8235597\", \"8397339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the in vivo phosphorylation sites controlling activity\", \"Cellular kinetics of translocation not yet resolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Resolved the regulatory logic: phosphorylation directly blocks DNA binding and calcineurin-mediated dephosphorylation upon Ca2+ signaling triggers nuclear translocation, defining the on-switch.\",\n      \"evidence\": \"32P labeling, in vitro calcineurin/alkaline phosphatase treatment, EMSA, and subcellular fractionation with FK506 inhibition in T cells\",\n      \"pmids\": [\"7657645\", \"7545680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Calcineurin docking interface on NFATC2 not yet mapped\", \"Off-switch kinases not identified\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapped the physical calcineurin\\u2013NFATC2 interaction and showed calcineurin activity bidirectionally controls activation state, completing the reversible activation/deactivation cycle.\",\n      \"evidence\": \"Calcineurin pulldown with FK506-FKBP12 competition; pharmacological manipulation (EGTA, CsA, ionomycin, PMA) with fractionation and EMSA\",\n      \"pmids\": [\"8576111\", \"8631904\", \"8668212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the rephosphorylating kinases for export not yet established\", \"Capacitative Ca2+ entry link only pharmacologically inferred\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the biochemical basis of cooperative NFAT-AP-1 enhancer assembly, showing strict spacing requirements and NFATC2-imposed AP-1 orientation that distinguish functional from non-functional composite sites.\",\n      \"evidence\": \"EMSA, methylation interference, DNase footprinting, affinity-cleaving, cross-linking and reporter assays on GM-CSF and IL-2 elements\",\n      \"pmids\": [\"7891702\", \"7583146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the orientation lock not yet visualized\", \"Coactivator recruitment not yet addressed\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Extended NFATC2 target repertoire to the TNF-\\u03b1 promoter, showing dual-site occupancy and cooperation with adjacent ATF-2/Jun is required for calcium-driven, CsA-sensitive induction.\",\n      \"evidence\": \"EMSA, promoter-reporter assays, site mutagenesis, and CsA inhibition in T cells\",\n      \"pmids\": [\"7982959\", \"8552071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether monomer vs dimer binding distinguishes TNF-\\u03b1 regulation not yet resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified VDR as a competitive repressor that blocks NFATC2/AP-1 complex formation at IL-2 and GM-CSF elements, revealing transcription-factor competition as a mode of NFAT regulation.\",\n      \"evidence\": \"In vitro competition with purified proteins, EMSA, GST coprecipitation with c-Jun, FLAG-VDR IP, and reporter rescue by NFAT overexpression\",\n      \"pmids\": [\"7565732\", \"10330159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts where VDR competition dominates not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Provided the structural mechanism by solving the NFATC2 dimer on a \\u03baB element, revealing a novel asymmetric Rel-homology dimerization mode distinct from other Rel proteins.\",\n      \"evidence\": \"X-ray crystallography of NFAT1 bound to HIV-1 LTR \\u03baB DNA; FRET/phasing analysis of cooperative DNA bending in the ternary complex\",\n      \"pmids\": [\"12949493\", \"9653115\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of dimerization not yet established at the time\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked the dimer structure to function, showing NFATC2 dimer-specific activation subdomains recruit CBP and confer dimer-dependent transcriptional output at the TNF element.\",\n      \"evidence\": \"Consensus site determination, DNase footprinting, transcriptional reporters, and coactivator interaction assays\",\n      \"pmids\": [\"19060202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo prevalence of dimer vs monomer binding genome-wide unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified kinase off-switches: p38 MAPK phosphorylates and drives CRM1-dependent export of NFATC2, distinguishing its regulation from NFATc.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, activated MKK6/p38 cotransfection, fractionation, and Leptomycin B inhibition\",\n      \"pmids\": [\"10788511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phospho-acceptor sites for p38 on NFATC2 not mapped\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated a non-immune, cell-intrinsic role: NFATC2 is required for a second phase of myoblast fusion and skeletal myotube growth.\",\n      \"evidence\": \"NFATC2-null primary myotubes, retroviral rescue, and morphometric measurement of size and myonuclear number\",\n      \"pmids\": [\"11309414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct muscle-growth target genes not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Placed prostaglandin F2\\u03b1/FP receptor signaling upstream of NFATC2 in muscle growth, the first prostaglandin-receptor\\u2013NFAT intersection.\",\n      \"evidence\": \"PGF2\\u03b1 treatment, NFAT reporter, and NFATC2-null myotube nuclear accretion assays\",\n      \"pmids\": [\"12695501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling steps linking FP receptor to calcineurin in muscle not detailed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed NFATC2 as a repressor of differentiation: loss causes spontaneous cartilage formation, establishing it as a brake on chondrogenesis.\",\n      \"evidence\": \"NFATp knockout mouse histology and chondrocyte-line overexpression with cartilage-marker analysis\",\n      \"pmids\": [\"10620601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Repressed chondrogenic target genes not molecularly defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed cytokine-context selectivity in repression: IL-15 recruits NFATC2 specifically to repress CX3CR1, contrasting with IL-2/NFAT2 activation of the same gene.\",\n      \"evidence\": \"ChIP for NFAT1/NFAT2, NFAT1 KO mice, CsA/VIVIT inhibitors, and \\u03baB-NFAT site mutation reporter assays\",\n      \"pmids\": [\"15347678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism converting NFATC2 from activator to repressor at this site unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined direct gene-control roles in immune differentiation and cell cycle: NFATC2 drives IL-4 (downstream of IL-6) and IL-21, and represses CDK4 via HDAC-sensitive promoter binding.\",\n      \"evidence\": \"NFATc2 KO T cells, IL-4 ELISA, NFAT reporters, ChIP/EMSA at IL-21, CDK4 promoter-reporters and CDK4 levels in calcineurin/NFATc2 KO mice\",\n      \"pmids\": [\"12093869\", \"12355451\", \"15684054\", \"12453415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch between activator and repressor functions at different promoters not mechanistically unified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established NFATC2 as an enforcer of tolerance/anergy in both B and T lymphocytes, framing it as a negative as well as positive immune regulator.\",\n      \"evidence\": \"NFAT1 KO crossed with anti-lysozyme anergy model; NFAT1-deficient antigen-specific CD4+ T cells in melanoma model\",\n      \"pmids\": [\"16849457\", \"22865456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Anergy-associated gene targets only partially defined\", \"Single-lab models for each phenotype\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified oncogenic activation routes: VRK2 phosphorylates NFAT1 at Ser-32 to boost COX-2-driven invasion, and NFAT1 transactivates MDM2 to suppress p53.\",\n      \"evidence\": \"In vitro kinase assay (Ser-32), co-IP, EMSA/ChIP at mdm2 P2 promoter, reporters, and invasion assays\",\n      \"pmids\": [\"23105117\", \"22787160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VRK2 and the calcineurin axis converge on the same activation pool unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved a context-specific GSK-3\\u03b2 role and chromatin mechanism in pancreatic cancer: GSK-3\\u03b2 stabilizes nuclear NFATc2 and NFATc2-STAT3 complexes, while NFATc2 builds Suv39H1/H3K9me3/HP1\\u03b3 heterochromatin to silence p15(INK4b).\",\n      \"evidence\": \"Co-IP, ChIP (H3K9me3, target promoters), DNA pulldown, reporters, and xenograft/GEMM models\",\n      \"pmids\": [\"26823495\", \"22079596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with GSK-3\\u03b2-driven NFAT degradation in other contexts not fully resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed NFAT downstream of Akt-GSK-3\\u03b2 signaling controlling proteasomal turnover and breast cancer migration, defining a degradation-based off-switch.\",\n      \"evidence\": \"GSK-3\\u03b2 shRNA/inhibitor, Akt-unresponsive GSK-3\\u03b2 mutants, NFAT reporter, proteasome inhibitors, and migration assays\",\n      \"pmids\": [\"19258413\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Degradation machinery and ubiquitin ligase not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined NFATC2 cancer transcriptional programs driving invasion, metastasis, stemness, and drug resistance through direct targets including IL8, MMP3, MMP-9, Ets1, and the SOX2/ALDH1A1 axis.\",\n      \"evidence\": \"ChIP/reporters at target promoters and enhancers, knockdown/rescue, Ca2+/calcineurin assays, CRISPR CRE deletion, sphere and xenograft/metastasis assays\",\n      \"pmids\": [\"28737489\", \"27013197\", \"32339381\", \"30467308\", \"25735562\", \"33754043\", \"26387540\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Many targets validated in single tumor types and single labs\", \"Direct ChIP missing for some targets\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapped genome-wide NFATC2 programs in non-immune proliferation and epigenetic activation: ~2200 \\u03b2-cell targets via Nr4a1 and FOXP cofactors, and dectin-1\\u2013induced H3K4me3 deposition at cytokine loci in dendritic cells.\",\n      \"evidence\": \"Active NFATC2 expression in human islets with RNA-seq/ChIP-seq/ATAC-seq, FOXP and Nr4a1 KO; ChIP-seq and H3K4me3 ChIP in dendritic cells\",\n      \"pmids\": [\"34491912\", \"25550437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link between NFATC2 and the H3K4 methyltransferase not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended NFATC2 regulation to T-cell exhaustion and microglial neuroinflammation: Dapl1/Tim3 restrains NFATc2 in CD8+ T cells, and LRRK2 phosphorylates NFATc2 to drive cytokine production via direct binding of inflammatory and proliferative promoters.\",\n      \"evidence\": \"Dapl1 KO mice with adoptive transfer/tumor models; LRRK2 KO/inhibition with nuclear fractionation and ELISA; microglia-specific Nfat1 KO with ChIP at Itgam/Tnf/Il1b/c-Myc\",\n      \"pmids\": [\"35773432\", \"33055242\", \"35892263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"LRRK2 phospho-site on NFATc2 not mapped\", \"Interplay between calcineurin and these alternative kinase inputs unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How NFATC2 is switched between activator and repressor at a given locus, and how competing kinase inputs (calcineurin, p38, GSK-3\\u03b2, VRK2, LRRK2) are integrated to set monomer vs dimer occupancy genome-wide, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking phosphorylation state to activator/repressor choice\", \"Determinants of monomer vs dimer binding in vivo unknown\", \"Cofactor code (CBP vs Suv39H1/HP1\\u03b3) selection not mechanistically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 6, 20, 23, 25, 26, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 6, 14, 26, 36]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [1, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 5, 12, 13, 28, 37]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 5, 12]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [14, 16, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 5, 12, 13, 24]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 6, 20, 23, 26, 32]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 21, 23, 42, 43, 45]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [25, 26, 30, 35, 36, 44]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [25, 33]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [20, 32]}\n    ],\n    \"complexes\": [\"NFAT-AP-1 (Fos-Jun) ternary complex\", \"NFATC2 asymmetric homodimer\", \"NFATc2-Suv39H1-HP1\\u03b3 repressor complex\", \"NFATc2-STAT3 complex\"],\n    \"partners\": [\"PPP3 (calcineurin)\", \"FOS\", \"JUN\", \"ATF2\", \"CREBBP (CBP)\", \"STAT3\", \"VDR\", \"STAT5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}